EMI Holding 10-Q 14 Nov 18 2018 Q3 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	9 Months Ended
	Sep. 30, 2018	Nov. 09, 2018
Document And Entity Information [Abstract]
Entity Registrant Name	EMMAUS LIFE SCIENCES, INC.
Entity Central Index Key	1,420,031
Document Type	10-Q
Trading Symbol	EMMA
Document Period End Date	Sep. 30, 2018
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Entity's Reporting Status Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	true
Entity Ex Transition Period	true
Entity Common Stock, Shares Outstanding		35,952,805
Document Fiscal Period Focus	Q3
Document Fiscal Year Focus	2,018

CONSOLIDATED BALANCE SHEETS

CONSOLIDATED BALANCE SHEETS - USD ($)	Sep. 30, 2018	Dec. 31, 2017
CURRENT ASSETS
Cash and cash equivalents	$ 16,662,211	$ 15,836,063
Restricted cash		6,720,000
Accounts receivable	1,415,208	26,814
Inventories, net	3,347,229	625,299
Investment in marketable securities	61,585,792	99,836,397
Marketable securities, pledged to creditor	345,510	160,925
Prepaid expenses and other current assets	319,143	290,371
Total current assets	83,675,093	123,495,869
PROPERTY AND EQUIPMENT, NET	152,490	105,302
OTHER ASSETS
Long-term investment at cost	572,199	65,520
Intangibles, net	57,120	67,200
Notes receivable	13,523
Deposits	335,148	111,581
Total other assets	977,990	244,301
Total assets	84,805,573	123,845,472
CURRENT LIABILITIES
Accounts payable and accrued expenses	7,542,026	5,695,310
Deferred rent	13,915	30,078
Other current liabilities	2,138,562	10,109
Warrant derivative liabilities		26,377,000
Notes payable, net	4,384,241	7,871,143
Notes payable to related parties, net	1,344,973	2,036,261
Convertible notes payable, net	14,137,645	7,025,002
Convertible notes payable to related parties, net	400,000	400,000
Total current liabilities	29,961,362	49,444,903
LONG-TERM LIABILITIES
Deferred rent	273,150	10,821
Other long-term liabilities	39,531,500	36,852,290
Warrant derivative liabilities	1,722,000	1,882,000
Notes payable, net	6,670,000
Conversion option liabilities		1,289,000
Convertible notes payable, net	5,258,462	20,075,780
Convertible notes payable to related parties, net	12,934,388
Total long-term liabilities	66,389,500	60,109,891
Total liabilities	96,350,862	109,554,794
STOCKHOLDERS’ EQUITY
Preferred stock — par value $0.001 per share, 20,000,000 shares authorized, none issued and outstanding
Common stock — par value $0.001 per share, 100,000,000 shares authorized, 35,952,805 shares and 34,885,506 shares issued and outstanding at September 30, 2018 and December 31, 2017, respectively	35,953	34,886
Additional paid-in capital	126,137,862	113,111,745
Accumulated other comprehensive income (loss)	(75,428)	41,275,785
Accumulated deficit	(137,643,676)	(140,131,738)
Total stockholders’ equity (deficit)	(11,545,289)	14,290,678
Total liabilities & stockholders’ equity	$ 84,805,573	$ 123,845,472

CONSOLIDATED BALANCE SHEETS (Pa

CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares	Sep. 30, 2018	Dec. 31, 2017
Statement Of Financial Position [Abstract]
Preferred stock, par value (in dollars per share)	$ 0.001	$ 0.001
Preferred stock, authorized	20,000,000	20,000,000
Preferred stock, issued	0	0
Preferred stock, outstanding	0	0
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, authorized	100,000,000	100,000,000
Common stock, issued	35,952,805	34,885,506
Common stock, outstanding	35,952,805	34,885,506

CONSOLIDATED STATEMENTS OF COMP

CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME LOSS (Unaudited) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Income Statement [Abstract]
REVENUES, NET	$ 4,882,246	$ 140,314	$ 8,234,657	$ 366,432
COST OF GOODS SOLD	141,200	128,618	496,580	222,130
GROSS PROFIT	4,741,046	11,696	7,738,077	144,302
OPERATING EXPENSES
Research and development	466,123	379,344	1,273,287	2,331,702
Selling	1,224,388	214,309	3,663,217	405,608
General and administrative	5,181,619	3,223,338	12,130,244	9,536,680
Total operating expenses	6,872,130	3,816,991	17,066,748	12,273,990
LOSS FROM OPERATIONS	(2,131,084)	(3,805,295)	(9,328,671)	(12,129,688)
OTHER INCOME (EXPENSE)
Other income	737,956		737,956
Loss on debt extinguishment			(3,244,769)
Change in fair value of warrant derivative liabilities	19,456,000	(10,542,000)	20,351,000	(16,204,000)
Change in fair value of embedded conversion option			466,000
Unrealized gain (loss) on investment in marketable securities	9,583,295		(24,066,019)
Loss on investment in marketable securities	(7,560,760)		(7,560,760)
Interest and other income (loss)	8,543	(15,051)	42,528	(36,992)
Interest expense	(5,524,687)	(2,904,336)	(16,268,533)	(7,164,130)
Total other income (expense)	16,700,347	(13,461,387)	(29,542,597)	(23,405,122)
INCOME (LOSS) BEFORE INCOME TAXES	14,569,263	(17,266,682)	(38,871,268)	(35,534,810)
INCOME TAXES			2,400	2,400
NET INCOME (LOSS)	14,569,263	(17,266,682)	(38,873,668)	(35,537,210)
COMPONENTS OF OTHER COMPREHENSIVE INCOME (LOSS)
Unrealized loss on investment in marketable securities		(14,203,879)		(14,616,291)
Unrealized gain (loss) in foreign translation	(5,916)	(1,090)	10,517	(12,095)
Other comprehensive income (loss)	(5,916)	(14,204,969)	10,517	(14,628,386)
COMPREHENSIVE INCOME (LOSS)	$ 14,563,347	$ (31,471,651)	$ (38,863,151)	$ (50,165,596)
NET INCOME (LOSS) PER COMMON SHARE	$ 0.42	$ (0.50)	$ (1.11)	$ (1.02)
WEIGHTED-AVERAGE COMMON SHARES OUTSTANDING	34,966,481	34,842,353	34,894,572	34,762,315

CONSOLIDATED STATEMENT OF CHANG

CONSOLIDATED STATEMENT OF CHANGES IN STOCKHOLDERS' EQUITY (unaudited) - 9 months ended Sep. 30, 2018 - USD ($)	Total	Common Stock [Member]	Additional Paid-In Capital [Member]	Accumulated Other Comprehensive Income (Loss) [Member]	Accumulated Deficit [Member]
Balance, beginning at Dec. 31, 2017	$ 14,290,678	$ 34,886	$ 113,111,745	$ 41,275,785	$ (140,131,738)
Balance, beginning (in shares) at Dec. 31, 2017		34,885,506
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Cumulative effect adjustment on adoption of ASU 2016-01				(41,361,730)	41,361,730
Beneficial conversion feature relating to convertible notes	10,218,609		10,218,609
Exercise of warrants	105,000	$ 30	104,970
Exercise of warrants (in Shares)		30,000
Stock issued for cash	275,000	$ 25	274,975
Stock issued for cash (in shares)		25,000
Repurchase of common stock and cancelled	(1,314,000)	$ (700)	(1,313,300)
Repurchase of common stock and cancelled		(700,000)
Share-based compensation	3,742,575		3,742,575
Exercise of common stock options (cashless)		$ 84	(84)
Exercise of common stock options (cashless) (in shares)		84,248
Exercise of warrants (cashless)		$ 1,628	(1,628)
Exercise of warrants (cashless) (in shares)		1,628,051
Foreign currency translation effect	10,517			10,517
Net loss	(38,873,668)				(38,873,668)
Balance, ending at Sep. 30, 2018	$ (11,545,289)	$ 35,953	$ 126,137,862	$ (75,428)	$ (137,643,676)
Balance, ending (in shares) at Sep. 30, 2018		35,952,805

CONSOLIDATED STATEMENT OF CHA_2

CONSOLIDATED STATEMENT OF CHANGES IN STOCKHOLDERS' DEFICIT (unaudited) (Parenthetical) - $ / shares	Sep. 30, 2018	Dec. 31, 2017
Statement Of Stockholders Equity [Abstract]
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, authorized	100,000,000	100,000,000

CONSOLIDATED STATEMENTS OF CASH

CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) - USD ($)	9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017
CASH FLOWS FROM OPERATING ACTIVITIES
Net loss	$ (38,873,668)	$ (35,537,210)
Adjustments to reconcile net loss to net cash flows from operating activities
Depreciation and amortization	43,671	18,593
Cost of scrapped inventory written off	11,191
Amortization of discount of convertible notes	13,056,693	5,695,652
Foreign exchange adjustments on convertible notes and notes payable	(21,611)	77,429
Realized loss on securities available-for-sale	7,560,760
Loss on debt extinguishment	3,244,769
Share-based compensation	3,742,575	3,751,371
Change in fair value of warrant derivative liabilities	(20,351,000)	16,204,000
Change in fair value of embedded conversion option	(466,000)
Unrealized loss on investment in marketable securities	24,066,019
Net changes in operating assets and liabilities
Investment capital reserve		(31,841,500)
Accounts receivable	(1,390,440)	4,141
Inventories	(2,735,009)	(226,934)
Prepaid expenses and other current assets	(39,230)	(89,282)
Deposits	(237,735)	106,879
Accounts payable and accrued expenses	2,586,359	1,639,275
Deferred rent	246,167	(11,349)
Other current liabilities	2,130,370	36,841,500
Other long-term liabilities	2,690,000
Net cash flows provided by (used in) operating activities	(4,736,119)	(3,367,435)
CASH FLOWS FROM INVESTING ACTIVITIES
Sale of marketable securities	6,439,240	0
Purchases of property and equipment	(80,892)	(86,215)
Purchase of marketable securities and investment at cost	(501,249)
Net cash flows provided by (used in) investing activities	5,857,099	(86,215)
CASH FLOWS FROM FINANCING ACTIVITIES
Repurchase of common stock and warrants	(7,500,000)
Proceeds from notes payable issued, net of issuance cost and discount	6,670,000	4,503,751
Proceeds from convertible notes payable issued, net of issuance cost and discount	17,644,700	1,200,000
Payments of notes payable	(4,200,000)	(344,339)
Payments of convertible notes	(20,000,000)
Proceeds from exercise of warrants	105,000
Proceeds from issuance of common stock	275,000	1,141,600
Net cash flows provided by (used in) financing activities	(7,005,300)	6,501,012
Effect of exchange rate changes on cash	(9,532)	50,606
Net increase (decrease) in cash, cash equivalents and restricted cash	(5,893,852)	3,097,968
Cash, cash equivalents and restricted cash, beginning of period	22,556,063	1,317,340
Cash, cash equivalents and restricted cash, end of period	16,662,211	4,415,308
SUPPLEMENTAL DISCLOSURES OF CASH FLOW ACTIVITIES
Interest paid	1,782,840	567,093
Income taxes paid	$ 2,400	2,400
SUPPLEMENTAL DISCLOSURES OF NON-CASH INFORMATION
Conversion of notes payable to common stock		200,000
Conversion of accrued interest payable to common stock		$ 10,079

BASIS OF PRESENTATION

BASIS OF PRESENTATION	9 Months Ended
	Sep. 30, 2018
Organization Consolidation And Presentation Of Financial Statements [Abstract]
BASIS OF PRESENTATION	NOTE 1 — BASIS OF PRESENTATION The accompanying unaudited consolidated interim financial statements of Emmaus Life Sciences, Inc. and subsidiaries (collectively, the “Company” or “Emmaus”) have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) on the basis that the Company will continue as a going concern. The consolidated financial statements include the accounts of the Company and its consolidated subsidiaries. All significant intercompany transactions have been eliminated. The Company’s unaudited consolidated interim financial statements contain adjustments, including normal recurring accruals necessary to present fairly the Company’s consolidated financial position, results of operations, comprehensive income (loss) and cash flows. Due to the uncertainty of the Company’s ability to meet its current operating and capital expenses, there is substantial doubt about the Company’s ability to continue as a going concern, as the continuation and expansion of its business is dependent upon obtaining further financing, market acceptance of Endari™, and achieving a profitable level of revenues. The consolidated interim financial statements do not include any adjustments that might result from the outcome of these uncertainties. The consolidated interim financial statements should be read in conjunction with the Company’s Annual Report on Form 10-K for the year ended December 31, 2017, filed with the Securities and Exchange Commission (“SEC”) on April 16, 2018 (the “Annual Report”). Interim results for the periods presented herein are not necessarily indicative of the results that may be expected for the fiscal year ending December 31, 2018. The preparation of the consolidated financial statements requires the use of management estimates. Actual results could differ materially from those estimates.

SUMMARY OF SIGNIFICANT ACCOUNTI

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	9 Months Ended
	Sep. 30, 2018
Accounting Policies [Abstract]
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	NOTE 2 — SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Refer to the Annual Report for a summary of significant accounting policies. There have been no material changes to the Company’s significant accounting policies during the nine months ended September 30, 2018 except for revenues, which are discussed below. Below are disclosures of certain interim balances, transactions, and significant assumptions used in computing fair value as of and for the three and nine months ended September 30, 2018 and comparative amounts from the prior fiscal periods: Revenues – Effective January 1, 2018, the Company adopted Accounting Standard codification (“ASC”) Topic 606, Revenue from Contracts with Customers using the modified retrospective transition methods. The adoption of ASC 606 did not have a material impact on the measurement or on the recognition of revenue of contracts for which all revenue had not been recognized as of January 1, 2018, therefore no cumulative adjustment has been made to the opening balance of accumulated deficit at the beginning of 2018. The comparative information has not been restated and continues to be reported under the accounting standards in effect for the periods presented. Since January 2018, the Company has generated revenues through the sale of Endari as a treatment for sickle cell disease (“SCD”). The Company also generates revenues to a much lesser extent from NutreStore L-glutamine powder, as well as AminoPure, a nutritional supplement. Revenues from Endari product sales are recognized upon transfer to our distributors, which are customers of the Company, when they obtain control of our products. These distributors subsequently resell our products to specialty pharmacy providers, health care providers, hospitals, patients and clinics. In addition to distribution agreements with these distributors, the Company enters into arrangements with specialty pharmacy providers, in-office dispensing providers, group purchasing organizations, and government entities that provide for government-mandated and/or privately-negotiated rebates, chargebacks and discounts with respect to the purchase of our products. These various discounts, rebates, and charge-backs are referred to as “variable consideration.” Revenues from product sales are recorded net of these variable considerations. Prior to recognizing revenues, the Company’s management forecasts and estimates variable consideration. Amounts of variable consideration are included in the transaction price to the extent that it is probable that a significant reversal in the amount of cumulative revenues recognized will not occur when the uncertainty associated with the variable consideration is subsequently resolved. Up until June 30, 2018, the Company recognized Endari sales revenues based upon the script data reports on shipments to patients as the Company did not have sufficient historical information to reliably forecast and estimate variable consideration and product returns. During the three months ended September 30, 2018, the Company obtained additional information based on new contracts signed with major distributors and pharmacies, knowledge of our reimbursement payor mix, as well as improved visibility as to the relatively fast turnover of Endari inventory at the distributor level. As such, the new information obtained in the three months ended September 30, 2018 provided the Company with the ability to better forecast and estimate the expected variable consideration related to sales to the distributors, which are customers of the Company, as well as establishing the expectation of a low level of product returns. The gross sales of Endari to these customers were $1.3 million, $3.8 million and $5.5 million for the three month periods ended March 31, June 30 and September 30 of 2018, respectively. The net revenues for Endari reported for these periods were $0.7 million, $2.3 million and $4.7 million for the three month periods ended March 31, June 30 and September 30 of 2018, respectively. The effect of being better able to forecast and estimate the expected variable consideration permitted the Company, in the three months ended September 30, 2018, to recognize $0.7 million in revenues that had been deferred in prior periods when the Company did not have sufficient historical information to reliably forecast and estimate variable consideration and product returns. Provisions for returns and other adjustments are provided for in the period in which the related revenues are recorded. Actual amounts of consideration ultimately received may differ from the management estimates. If actual results in the future vary from the estimates, the management will adjust these estimates, which would affect net product revenues in the period such variances become known. The following are our significant categories of sales discounts and allowances: Sales Discounts: The Company provides its customers prompt payment discounts that are explicitly stated in its contracts and are recorded as a reduction of revenues in the period the revenues are recognized. Product Returns: The Company offers its distributors a right to return product purchased directly from the Company, which is principally based upon (i) overstocks, (ii) inactive product or non-moving product due to market conditions, and (iii) expired products. Product return allowances are estimated and recorded at the time of sale. Government Rebates: The Company is subject to discount obligations under state Medicaid programs and the Medicare prescription drug coverage gap program. The Company’s management estimates Medicaid and Medicare prescription drug coverage gap rebates based upon a range of possible outcomes that are probability-weighted for the estimated payor mix. These reserves are recorded in the same period the related revenues are recognized, resulting in a reduction of product revenues and the establishment of a current liability that is included as an accrued liability in our balance sheet. The liability for these rebates consists primarily of estimates of claims expected to be received in future periods related to recognized revenues. Chargebacks and Discounts: Chargebacks for fees and discounts represent the estimated obligations resulting from contractual commitments to sell products to certain specialty pharmacy providers, in-office dispensing providers, group purchasing organizations, and government entities at prices lower than the list prices charged to distributors. The distributors charge the Company for the difference between what they pay for the products and the Company’s contracted selling price to these specialty pharmacy providers, in-office dispensing providers, group purchasing organizations, and government entities. These reserves are established in the same period that the related revenues are recognized, resulting in a reduction of revenues. Chargeback amounts are generally determined at the time of resale of products by the distributors. Inventories — All of the raw material purchased during the nine months ended September 30, 2018 were from two vendors and for the year ended December 31, 2017 were from one vendor. The below table presents inventory by category: Inventories by category September 30, 2018 December 31, 2017 Raw materials and components $ 184,126 $ — Work-in-process 924,275 124,801 Finished goods 2,238,828 500,498 Total $ 3,347,229 $ 625,299 Advertising cost — Advertising costs are expensed as incurred. Advertising costs for the three months ended September 30, 2018 and 2017 were $16,750 and $18,201, respectively. Advertising costs for the nine months ended September 30, 2018 and 2017 were $76,654 and $35,399, respectively. Marketable securities — The Company’s marketable securities consist of the following securities; (a) 39,250 shares of capital stock of CellSeed, Inc. (“CellSeed”) those that remain of the 147,100 shares acquired in January 2009 for ¥100,028,000 Japanese Yen (JPY) (equivalent to $1.1 million USD), at ¥680 JPY per share; (b) 849,744 shares of capital stock of KPM Tech Co., Ltd. (“KPM”) which were acquired in October 2016 for ₩14,318,186,400 South Korean Won (KRW) (equivalent to $13.0 million USD) at ₩16,850 KRW per share; (c) 271,950 shares of capital stock of Hanil Vacuum Co., Ltd. (“Hanil”) which were acquired in October 2016 for ₩1,101,397,500 KRW (equivalent to $1.0 million USD) at ₩4,050 KRW per share; and (d) 6,643,559 shares of capital stock of Telcon, Inc. (“Telcon”) which were acquired in July 2017 for ₩36,001,446,221 KRW (equivalent to $31.8 million USD) at ₩5,419 KRW per share. As of September 30, 2018 and December 31, 2017, the closing prices per CellSeed share on the Tokyo Stock Exchange were ¥1,001 ($8.80 USD) and ¥462 JPY ($4.10 USD), respectively, and the closing prices per Telcon share on the Korean Securities Dealers Automated Quotations (“KOSDAQ”) were ₩10,300 ($9.27 USD) and ₩14,900 KRW ($13.95 USD), respectively. As of December 31, 2017, the closing price per KPM share on KOSDAQ was ₩1,625 KRW ($1.52 USD) and the closing price per Hanil share on KOSDAQ was ₩2,830 KRW ($2.65 USD). During the three months ended September 30, 2018, the Company sold all of its KPM and Hanil shares. As of September 30, 2018, and December 31, 2017, 39,250 shares of CellSeed common stock were pledged to secure a $300,000 convertible note of the Company issued to Mitsubishi UFJ Capital III Limited Partnership that is due on demand and were classified as current assets, as marketable securities, pledged to creditor. In addition, as of September 30, 2018 and December 31, 2017 6,643,559 shares of Telcon were pledged to secure the API Supply Agreement (see Note 8) in which Emmaus received $31,800,000 related to a trade advance discount. These shares were classified as current assets, as investment in marketable securities Prepaid expenses and other current assets — Prepaid expenses and other current assets consisted of the following at September 30, 2018 and December 31, 2017: September 30, 2018 December 31, 2017 Prepaid insurance $ 72,510 $ 132,387 Other prepaid expenses and current assets 246,633 157,984 Total prepaid expenses $ 319,143 $ 290,371 Other long-term liabilities —Other long-term liabilities consisted of the following at September 30, 2018 and December 31, 2017: September 30, 2018 December 31, 2017 Trade discount $ 29,531,500 $ 31,841,500 Unearned revenue 10,000,000 5,000,000 Other long-term liabilities — 10,790 Total other long-term liabilities $ 39,531,500 $ 36,852,290 The Company has entered into an API Supply Agreement (the “API Agreement”) with Telcon pursuant to which Telcon advanced to the Company approximately ₩36.0 billion KRW (approximately $31.8 million USD) as a trade discount to supply 25% of the Company’s requirements for bulk containers of pharmaceutical grade L-glutamine (“PGLG”) for a term of five years, with 10 one-year renewal terms. The agreement will automatically renew unless terminated by either party in writing. The agreement does not include yearly purchase commitments or margin guarantees. The advance trade discount will be applied against purchases made by the Company from Telcon over the life of the agreement. Fair value measurements — The following table presents the activity for those items measured at fair value on a recurring basis using Level 3 inputs during the nine months ended September 30, 2018 and the year ended December 31, 2017: Nine Months Ended Year Ended Warrant Derivative Liabilities—Stock Purchase Warrants September 30, 2018 December 31, 2017 Balance, beginning of period $ 26,377,000 $ 10,600,000 Repurchased (6,186,000 ) — Change in fair value included in the statement of comprehensive income (loss) (20,191,000 ) 15,777,000 Balance, end of period $ — $ 26,377,000 The following table presents warrants issued to GPB Debt Holdings II, LLC as described in Note 7 measured at fair value as of September 30, 2018: Nine Months Ended September 30, 2018 Year Ended December 31, 2017 Liability Instrument—GPB Warrants Embedded Conversion Option Warrants Embedded Conversion Option Balance, beginning of period $ 1,882,000 $ 1,289,000 $ — $ — Fair value at issuance date — — 1,882,000 1,289,000 Change in fair value included in the statement of comprehensive income (loss) (160,000 ) (466,000 ) — — Extinguished upon debt repayment — (823,000 ) — — Balance, end of period $ 1,722,000 $ — $ 1,882,000 $ 1,289,000 The value of warrant derivative liabilities and the change in fair value of the warrant derivative liabilities were determined using a Binomial Monte-Carlo Cliquet (aka “Ratchet”) Option Pricing Model. The model is similar to traditional Black-Scholes-type option pricing models, except that the exercise price resets at certain dates in the future. The value as of the dates set forth in the table below, was based on upon following assumptions: September 30, 2018 December 31, 2017 Stock price $ 11.10 $ 11.40 Risk‑free interest rate 2.92 % 2.20 % Expected volatility (peer group) 70.00 % 70.00 % Expected life (in years) 4.25 5.00 Expected dividend yield — — Number outstanding 240,764 240,764 Balance, end of period: Warrant derivative liabilities (long-term) $ 1,722,000 $ 1,882,000 Debt and related party debt — The following table presents the effective interest rates on loans originated and refinanced in the respective periods that either had a beneficial conversion feature or an attached warrant: Type of Loan Term of Loan Stated Annual Interest Original Loan Principal Amount Conversion Rate Beneficial Conversion Discount Amount Warrants Issued with Notes Exercise Price Warrant FMV Discount Amount Effective Interest Rate Including Discounts 2017 convertible notes payable Due on demand - 3 years 10% - 13.5% $ 36,113,296 $3.50 - $10.31 $ 11,678,725 240,764 $ 10.80 $ 1,882,000 10% - 110% 2018 convertible notes payable Due on demand - 2 years 6% - 10% 26,501,808 $3.50 - $10.00 10,218,609 — — — 19% - 110% $ 62,615,104 $ 21,897,334 240,764 $ 1,882,000 Related party notes are disclosed as separate line items in the Company’s consolidated balance sheets. Net loss per share — As of September 30, 2018 and 2017, respectively, potentially dilutive securities exercisable or convertible into 15,286,940 and 15,617,245 shares of Company common stock were outstanding. No potentially dilutive securities were included in the calculation of diluted net loss per share since their effect would be anti-dilutive for all periods presented. Recent accounting pronouncements —In January 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2016-01, Recognition and Measurement of Financial Assets and Financial Liabilities . The amendments applicable to the Company in this Update (1) supersede the guidance to classify equity securities, except equity method securities, with readily determinable fair values into trading or available-for-sale categories and require equity securities to be measured at fair value with changes in the fair value recognized through net income, (2) allow equity investments that do not have readily determinable fair values to be remeasured at fair value either upon the occurrence of an observable price change or upon identification of an impairment, (3) require assessment for impairment of equity investments without readily determinable fair values qualitatively at each reporting period, (4) eliminate the requirement to disclose the methods and significant assumptions used in calculating the fair value of financial instruments required to be disclosed for financial instruments measured at amortized cost on the balance sheet, (5) require public business entities to use the exit price notion when measuring the fair value of financial instruments for disclosure purposes, (6) require separate presentation of financial assets and financial liabilities by measurement category and form of financial asset (that is, securities or loans and receivables) on the balance sheet or the accompanying notes to the financial statements, (7) clarify that an entity should evaluate the need for a valuation allowance on a deferred tax asset related to available-for-sale securities in combination with the entity’s other deferred tax assets. This Update was effective beginning January 1, 2018 and the Company is now recognizing any changes in the fair value of certain equity investments in net income as prescribed by the new standard rather than in other comprehensive income. The Company recognized a cumulative effect adjustment to increase the opening balance of retained earnings as of January 1, 2018 by $41.4 million, net of $12.3 million income tax benefit. Refer to Note 4 for additional disclosures required by this ASU. In February 2016, the FASB issued ASU No. 2016-02, Leases Targeted Improvements In April 2016, the FASB issued ASU 2016-10, Revenue from Contracts with Customers (Topic 606): Identifying Performance Obligations and Licensing In July 2017, the FASB issued ASU No. 2017-11, Earnings Per Share (Topic 260) Distinguishing Liabilities from Equity (Topic 480) Derivatives and Hedging (Topic 815): I. Accounting for Certain Financial Instruments with Down Round Features, II. Replacement of the Indefinite Deferral for Mandatorily Redeemable Financial Instruments of Certain Nonpublic Entities and Certain Mandatorily Redeemable Noncontrolling Interests with a Scope Exception. In February 2018, the FASB issued ASU No. 2018-02, Income Statement – Reporting Comprehensive Income (Topic 220): Reclassification of Certain Tax Effects from Accumulated Other Comprehensive Income In February 2018, the FASB issued ASU No. 2018-03, Technical Corrections and Improvements to Financial Instruments—Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities Fair Value Measurement Derivatives and Hedging— Embedded Derivatives Financial Instruments— Overall In June 2018, the FASB issued ASU No. 2018-07, Compensation – Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting In August 2018, the FASB issued ASU No. 2018-13, Fair Value Measurement (Topic 820): Disclosure Framework – Changes to the Disclosure Requirements for Fair Value Measurement accompanying footnote disclosures In August 2018, the FASB issued ASU 2018-15, Intangibles – Goodwill and Other – Internal-Use Software (Subtopic 350-40) Customer’s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That is a Service Contract

PROPERTY AND EQUIPMENT

PROPERTY AND EQUIPMENT	9 Months Ended
	Sep. 30, 2018
Property Plant And Equipment [Abstract]
PROPERTY AND EQUIPMENT	NOTE 3 — PROPERTY AND EQUIPMENT Property and equipment consisted of the following at: September 30, 2018 December 31, 2017 Equipment $ 292,212 $ 225,615 Leasehold improvements 70,249 61,054 Furniture and fixtures 79,001 74,090 Subtotal 441,462 360,759 Less: accumulated depreciation (288,972 ) (255,457 ) Total $ 152,490 $ 105,302 During the three months ended September 30, 2018 and 2017, depreciation expense was $12,843 and $9,236 , respectively. During the nine months ended September 30, 2018 and 2017, depreciation expense was $33,591 and $18,593, respectively.

INVESTMENTS

INVESTMENTS	9 Months Ended
	Sep. 30, 2018
Investments [Abstract]
INVESTMENTS	NOTE 4 — INVESTMENTS Equity Securities— Effective January 1, 2018, the Company adopted ASU 2016-01 which requires the Company to measure all equity investments that do not result in consolidation and are not accounted for under the equity method at fair value and recognize any changes in earnings. The Company use quoted market prices to determine the fair value of equity securities with readily determinable fair values. For equity securities without readily determinable fair values, the Company has elected the measurement alternative under which the Company measures these investments at cost minus impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for the identical or a similar investment of the same issuer. Management assesses each of these investments on an individual basis. Additionally, on a quarterly basis, management is required to make a qualitative assessment of whether the investment is impaired. During the nine months ended September 30, 2018, the Company did not recognize any fair value adjustments for equity securities without readily determinable fair values. The Company recognized a cumulative effect adjustment of $41.4 million, net of $12.3 million income tax benefit, to increase the opening balance of retained earnings with an offset to accumulated other comprehensive income as of January 1, 2018, in connection with the adoption of ASU 2016-01. For fiscal periods beginning prior to January 1, 2018, marketable equity securities not accounted for under the equity method were classified as available-for-sale. There were no marketable equity securities classified as trading. For equity securities classified as available-for-sale, realized gains and losses were included in net loss. Unrealized gains and losses on equity securities classified as available-for-sale were recognized in accumulated other comprehensive income (loss), net of deferred taxes. In addition, the Company had equity securities without readily determinable fair values that were recorded at cost. For these cost method investments, the Company recorded dividend income, if any, when applicable dividends were declared. Cost method investments were reported as other investments in our consolidated balance sheets, and dividend income from cost method investments was reported in other income (loss) net in our consolidated statements of comprehensive loss. The Company reviewed all of its cost method investments quarterly to determine if impairment indicators were present; however, the Company was not required to determine the fair value of these investments unless impairment indicators existed. When impairment indicators did exist, the Company generally used discounted cash flow analyses to determine the fair value. The Company estimated that the fair values of its cost method investments approximated their carrying values as of December 31, 2017. The Company’s cost method investments had a carrying value of $65,520 as of December 31, 2017. As of September 30, 2018, the carrying values of our equity securities were included in the following line items in our consolidated balance sheets: At September 30, 2018 Fair Value with Changes Recognized in Income Measurement Alternative - No Readily Determinable Fair Value Marketable securities $ 61,931,302 $ — Other investments — 572,199 Total equity securities $ 61,931,302 $ 572,199 The calculation of net unrealized gains and losses for the period that relate to equity securities still held at September 30, 2018 is as follows: Nine Months Ended September 30, 2018 Net losses recognized during the period related to equity securities $ (31,626,779 ) Less: Net gain (loss) recognized during the period related to equity securities sold during the period (7,560,760 ) Unrealized gain (loss) recognized during the period related to equity securities still held at the end of the period $ (24,066,019 ) As of December 31, 2017, equity securities consisted of the following: Gross Unrealized Estimated Cost Gains Losses Fair Value Trading securities $ — $ — $ — $ — Available-for-sale securities 46,209,017 60,812,231 (6,958,406 ) 100,062,842 Total equity securities $ 46,209,017 $ 60,812,231 $ (6,958,406 ) $ 100,062,842 As of December 31, 2017, the Company had investments classified as available-for-sale in which our cost basis exceeded the fair value of our investment. Management assessed each of the investment in marketable securities that were in a gross unrealized loss position to determine if the decline in fair value was other than temporary. Management's assessment as to the nature of a decline in fair value is based on, among other things, the length of time and the extent to which the market value has been less than our cost basis; the financial condition and near-term prospects of the issuer, and the Company’s intent to retain the investment for a period of time sufficient to allow for any anticipated recovery in market value. As a result of these assessments, management determined that the decline in fair value of these investments and did not record any impairment charges. As of December 31, 2017, the fair values of our equity securities were included in the following line items in our consolidated balance sheets: Available-for-Sale Securities Marketable securities $ 99,997,322 Long-term investment at cost 65,520 Total equity securities $ 100,062,842 During the nine months ended September 30, 2018, the Company sold all of its KPM Tech and Hanil shares.

ACCOUNTS PAYABLE AND ACCRUED EX

ACCOUNTS PAYABLE AND ACCRUED EXPENSES	9 Months Ended
	Sep. 30, 2018
Payables And Accruals [Abstract]
ACCOUNTS PAYABLE AND ACCRUED EXPENSES	NOTE 5 — ACCOUNTS PAYABLE AND ACCRUED EXPENSES Accounts payable and accrued expenses consisted of the following: September 30, 2018 December 31, 2017 Accounts payable: Regulatory fees $ — $ 715,999 Clinical and regulatory expenses 296,316 116,736 Commercialization consulting fees 8,544 30,000 Manufacturing cost 394,093 217,155 Legal expenses 60,526 87,701 Consulting fees 224,850 147,038 Accounting fees 25,770 67,293 Selling expenses 380,604 35,383 Investor relations and public relations expenses - 45,526 Board member compensation 278,740 11,200 Other vendors 976,095 125,605 Total accounts payable 2,645,538 1,599,636 Accrued interest payable, related parties 506,322 318,120 Accrued interest payable 1,976,563 1,449,154 Accrued expenses: Wages and payroll taxes payable 95,021 1,711,541 Deferred salary 291,667 291,667 Paid vacation payable 251,288 186,978 Other accrued expenses 1,775,627 138,214 Total accrued expenses 2,413,603 2,328,400 Total accounts payable and accrued expenses $ 7,542,026 $ 5,695,310

NOTES PAYABLE

NOTES PAYABLE	9 Months Ended
	Sep. 30, 2018
Debt Disclosure [Abstract]
NOTES PAYABLE	NOTE 6 — NOTES PAYABLE Notes payable consisted of the following at September 30, 2018 and December 31, 2017: Year Issued Interest Rate Range Term of Notes Conversion Price Principal Outstanding September 30, 2018 Discount Amount September 30, 2018 Carrying Amount September 30, 2018 Shares Underlying Notes September 30, 2018 Principal Outstanding December 31, 2017 Discount Amount December 31, 2017 Carrying Amount December 31, 2017 Shares Underlying Notes December 31, 2017 Notes payable 2013 10% Due on demand — $ 879,400 $ — $ 879,400 — $ 887,600 $ — $ 887,600 — 2015 10% Due on demand — 10,000 — 10,000 — — — — — 2016 10% - 11% Due on demand — 843,335 — 843,335 — 833,335 — 833,335 — 2017 11% Due on demand — 2,540,506 — 2,540,506 — 6,150,208 — 6,150,208 — 2018 10% - 11% Due on demand - 18 months — 6,811,000 30,000 6,781,000 — — — — — $ 11,084,241 $ 30,000 $ 11,054,241 — $ 7,871,143 $ — $ 7,871,143 — Current $ 4,384,241 $ — $ 4,384,241 — $ 7,871,143 $ — $ 7,871,143 — Non-current $ 6,700,000 $ 30,000 $ 6,670,000 — $ — $ — $ — — Notes payable - related party 2015 11% Due on demand — — — — — 310,000 — 310,000 — 2016 10% Due on demand — 270,000 — 270,000 — 810,510 — 810,510 — 2017 10% Due on demand — 915,751 — 915,751 — 915,751 — 915,751 — 2018 11% Due on demand — 159,222 — 159,222 — — — — — $ 1,344,973 $ — $ 1,344,973 — $ 2,036,261 $ — $ 2,036,261 — Current $ 1,344,973 $ — $ 1,344,973 — $ 2,036,261 $ — $ 2,036,261 — Non-current $ — $ — $ — — $ — $ — $ — — Convertible notes payable 2011 10% 5 years $ 3.05 $ 300,000 $ — $ 300,000 98,285 $ 300,000 $ — $ 300,000 98,285 2014 10% Due on demand - 2 years $3.05 - $3.60 501,273 — 501,273 176,777 486,878 — 486,878 168,766 2016 10% 1 year - 2 years $3.60 - $4.50 182,495 7,952 174,543 55,983 1,516,329 83,298 1,433,031 441,048 2017 10% Due on demand - 2 years $3.50 - $10.00 5,256,547 947,731 4,308,816 1,441,824 36,113,296 11,232,423 24,880,873 5,357,488 2018 6% - 10% Due on demand - 2 years $3.50 - $10.00 16,522,996 2,411,522 14,111,474 2,983,385 — — — — $ 22,763,311 $ 3,367,205 $ 19,396,106 4,756,254 $ 38,416,503 $ 11,315,721 $ 27,100,782 6,065,587 Current $ 16,256,710 $ 2,119,066 $ 14,137,644 2,119,066 $ 12,860,912 $ 5,835,910 $ 7,025,002 3,449,984 Non-current $ 6,506,601 $ 1,248,139 $ 5,258,462 2,637,188 $ 25,555,591 $ 5,479,811 $ 20,075,780 2,615,603 Convertible notes payable - related party 2012 10% Due on demand $ 3.30 $ 200,000 $ — $ 200,000 71,127 $ 200,000 $ — $ 200,000 68,122 2015 10% 2 years $ 4.50 200,000 — 200,000 56,109 200,000 — 200,000 53,905 2017 10% 2 years $ 10.00 5,000,000 407,292 4,592,708 507,465 — — — — 2018 10% 2 years $ 10.00 9,400,000 1,058,320 8,341,680 971,577 — — — — $ 14,800,000 $ 1,465,612 $ 13,334,388 1,606,278 $ 400,000 $ — $ 400,000 122,027 Current $ 400,000 $ — $ 400,000 127,236 $ 400,000 $ — $ 400,000 122,027 Non-current $ 14,400,000 $ 1,465,612 $ 12,934,388 1,479,042 $ — $ — $ — — Total $ 49,992,525 $ 4,862,817 $ 45,129,708 6,362,532 $ 48,723,907 $ 11,315,721 $ 37,408,186 6,187,614 The weighted-average stated interest rates of notes payable as of September 30, 2018 and December 31, 2017 were 10% and 11%, respectively. The weighted average effective interest rates of notes payable for the nine-month period ended September 30, 2018 and the year ended December 31, 2017 were 38% and 24% respectively, after giving effect to discounts relating to beneficial conversion features and the fair value of warrants issued in connection with these notes. The notes payable and convertible notes payable do not have restrictive financial covenants or acceleration clauses associated with a material adverse change event. The holders of the convertible notes have the option to convert their notes into Company common stock at the stated conversion price during the term of their convertible notes. Conversion prices on these convertible notes payable range from $3.05 to $10.00 per share. Certain notes with a $4.50 or a $10.00 stated conversion price in the second year of their two-year term are subject to automatic conversion into shares of Company common stock at a conversion price equal to 80% of the initial public offering price at the time of a qualified public offering. All notes due on demand are treated as current liabilities. Contractual principal payments due on notes payable are as follows: 2018 (three months) $ 20,894,505 2019 6,491,419 2020 22,606,601 Total $ 49,992,525 The Company estimated the total fair value of any beneficial conversion feature and accompanying warrants in allocating the note proceeds. The proceeds allocated to the beneficial conversion feature were determined by taking the estimated fair value of shares issuable under the convertible notes less the fair value of the number of shares that would be issued if the conversion rate equaled the fair value of Company common stock as of the date of issuance (see Note 2). The fair value of the warrants issued in conjunction with notes was determined using the Black Scholes Merton Option Pricing Model with the following inputs for the period ended December 31, 2017. 2018 2017 Stock price — $ 11.40 Exercise price — $ 10.80 Term — 5 years Risk‑free interest rate — 2.20 % Expected dividend yield — — Expected volatility — 70.0 % In situations where the notes included both a beneficial conversion feature and a warrant, the proceeds were allocated to the warrants and beneficial conversion feature based on their respective pro rata fair values. The Company did not issue any warrants in conjunction with notes in the nine months ended September 30, 2018.

STOCKHOLDERS' DEFICIT

STOCKHOLDERS' DEFICIT	9 Months Ended
	Sep. 30, 2018
Stockholders Equity Note [Abstract]
STOCKHOLDERS' DEFICIT	NOTE 7 — STOCKHOLDERS’ DEFICIT Private placement — On September 11, 2013, the Company issued an aggregate of 3,020,501 units at a price of $2.50 per unit (the “Private Placement”). Each unit consisted of one share of common stock and one common stock warrant for the purchase of an additional share of common stock. The aggregate purchase price for the units was $7,551,253. In addition, 300,000 warrants for the purchase of a share of common stock were issued to a broker under the same terms as the Private Placement transaction (the “Broker Warrants”). The warrants issued in the Private Placement and the Broker Warrants entitle the holders thereof to purchase, at any time on or prior to September 11, 2018, shares of common stock of the Company at an exercise price of $3.50 per share. The warrants contain non-standard anti-dilution protection and, consequently, are being accounted for as liabilities, were originally recorded at fair value, and are adjusted to fair market value each reporting period. Because the shares of common stock underlying the Private Placement warrants and Broker Warrants were not effectively registered for resale by September 11, 2014, the warrant holders have an option to exercise the warrants using a cashless exercise feature. The shares have not been registered for resale as of September 30, 2018. The availability to warrant holders of the cashless exercise feature as of September 11, 2014 caused the then-outstanding 2,225,036 Private Placement warrants and Broker Warrants with fair value of $7,068,000 to be reclassified from liability classified warrants to warrant derivative liabilities and to continue to be remeasured at fair value each reporting period. On June 10, 2014, certain warrant holders exercised 1,095,465 warrants issued in the Private Placement for the exercise price of $3.50 per share, resulting in the Company receiving aggregate exercise proceeds of $3.8 million and issuing 1,095,465 shares of common stock. Prior to exercise, these Private Placement warrants were accounted for at fair value as liability classified warrants. As of June 10, 2014, immediately prior to exercise, the carrying value of these Private Placement warrants was reduced to their fair value of $1.8 million, representing their intrinsic value, with this adjusted carrying value of $1.8 million being transferred to additional paid-in capital. Also on June 10, 2014, based on an offer made to holders of Private Placement warrants in connection with such exercises, the Company issued an aggregate of 1,095,465 replacement warrants to holders exercising Private Placement warrants, which replacement warrants have terms that are generally the same as the exercised warrants, including an expiration date of September 11, 2018 and an exercise price of $3.50 per share. The replacement warrants are treated for accounting purposes as liability classified warrants, and their issuance gave rise to a $3.5 million warrant exercise inducement expense based on their fair value as of issuance as determined using a Binomial Monte-Carlo Cliquet (aka Ratchet) Option Pricing Model. Because the shares of common stock underlying the replacement warrants were not effectively registered for resale by June 10, 2015, the warrant holders have an option to exercise the warrants using a cashless exercise feature. The availability to warrant holders of the cashless exercise feature as of June 10, 2015 caused the then-outstanding 1,095,465 replacement warrants with fair value of $2,545,000 to be reclassified from liability classified warrants to warrant derivative liabilities and to continue to be remeasured at fair value each reporting period. As of September 11, 2018, all of the Private Placement warrants, replacement warrants and Broker Warrants had been exercised primarily on a cashless basis, or had expired. A summary of outstanding warrants as of September 30, 2018 and December 31, 2017 is presented below: Nine Months Ended Year Ended September 30, 2018 December 31, 2017 Warrants outstanding, beginning of period 5,265,432 5,024,668 Granted 202,000 240,764 Exercised (2,384,817 ) — Cancelled, forfeited and expired (985,684 ) — Warrants outstanding, end of period 2,096,931 5,265,432 A summary of outstanding warrants by year issued and exercise price as of September 30, 2018 is presented below: Outstanding Exercisable Year issued and Exercise Price Number of Warrants Issued Weighted Average Remaining Contractual Life (Years) Weighted Average Exercise Price Total Weighted Average Exercise Price At December 31, 2014 $ 3.50 50,000 0.58 $ 3.50 50,000 $ 3.50 2014 Total 50,000 50,000 At December 31, 2015 $ 4.90 110,417 1.43 $ 4.90 110,417 $ 4.90 2015 Total 110,417 110,417 At December 31, 2016 $ 4.50 118,750 2.75 $ 4.50 118,750 $ 4.50 $ 4.70 75,000 2.59 $ 4.70 75,000 $ 4.70 $ 5.00 1,300,000 2.61 $ 5.00 1,300,000 $ 5.00 2016 Total 1,493,750 1,493,750 At December 31, 2017 $ 10.80 240,764 4.75 $ 10.80 240,764 $ 10.80 2017 Total 240,764 240,764 At September 30, 2018 $ 11.30 202,000 4.86 $ 11.30 202,000 $ 11.30 Grand Total 2,096,931 2,096,931 Stock options — During the nine months ended September 30, 2018, the Company granted 357,000 options to its officers, directors and employees. Of these options, 30,000 will equally vest one-third on each of the first three anniversaries of the grant date, have an exercise price of $11.40 per share and are exercisable through 2028, 277,000 options will vest over three years starting August 8, 2018, have an exercise price of $11.30 per share and are exercisable through 2028, 50,000 options will vest over three years starting September 27, 2018, have an exercise price of $11.10 per share and are exercisable through 2028. During the year ended December 31, 2017, 50,000 options were granted by the Company’s Board of Directors to a consultant. These options vested immediately, have an exercise price of $11.40 per share and are exercisable through 2027. As of September 30, 2018, there were 6,835,534 options outstanding under the Company’s 2011 Stock Incentive Plan. Summaries of outstanding options as of September 30, 2018 and December 31, 2017 are presented below. September 30, 2018 December 31, 2017 Number of Options Weighted‑ Average Exercise Price Number of Options Weighted‑ Average Exercise Price Options outstanding, beginning of period 6,775,200 $ 4.12 6,955,200 $ 4.10 Granted or deemed issued 357,000 $ 11.28 50,000 $ 11.40 Exercised (170,000 ) $ 4.59 (11,895 ) $ 4.19 Cancelled, forfeited and expired (126,666 ) $ 5.43 (218,105 ) $ 4.98 Options outstanding, end of period 6,835,534 $ 4.46 6,775,200 $ 4.12 Options exercisable, end of period 5,985,823 $ 4.02 5,604,439 $ 3.95 Options available for future grant 2,164,466 2,224,800 During the nine months ended September 30, 2018 and 2017, the Company recognized $3.7 million and $3.8 million, respectively, of share-based compensation expense arising from stock options. As of September 30, 2018, there was $3.8 million of total unrecognized compensation expense related to unvested share-based compensation arrangements granted under the Company’s 2011 Stock Incentive Plan. That expense is expected to be recognized over the weighted-average remaining period of 2.0 years. Registration rights — Pursuant to the Purchase Warrant relating to the GPB Debt Holdings II, LLC issued by the Company on December 29, 2017, the Company entered into a Registration Rights Agreement (the “Registration Rights Agreement”) pursuant to which the Company has agreed to file a registration statement with the Securities and Exchange Commission (the “Commission”) relating to the offer and sale by GPB of the Company Shares underlying the Warrants. The Company is required to file a registration statement within one hundred eighty (180) days of closing of a public listing of the Company’s Common Stock for trading on any national securities exchange (excluding any over-the-counter market), whether through a direct listing application or merger transaction. The Company is required to have the registration statement become effective on the earlier of (A) the date that is two-hundred and forty (240) days following the later to occur of (i) the date of closing of the public listing or (ii) or in the event the registration statement receives a “full review” by the Commission, the date that is 300 days following the date of closing of the public listing, or (B) the date which is within three (3) business days after the date on which the Commission informs the Company (i) that the Commission will not review the registration statement or (ii) that the Company may request the acceleration of the effectiveness of the registration statement. If the Company does not effect such registration within that period of time, it will be required to pay GPB for liquidated damages an amount of cash equal to 2% of the product of (i) the number of Registrable Securities and (ii) the Closing Sale Price or Closing Bid Price as of the trading day immediately prior to the Event Date, such payments to be made on the Event Date and every thirty (30) day anniversary thereafter with a maximum penalty of 12% until the applicable Event is cured; provided, however, that in the event the Commission does not permit all of the Registrable Securities to be included in the Registration Statement because of its application of Rule 415, liquidated damages shall only be payable by the Company based on the portion of the Holder’s initial investment in the Securities that corresponds to the number of such Holder’s Registrable Securities permitted to be registered by the Commission in such Registration Statement pursuant to Rule 415. Pursuant to the Subscription Agreements relating to the Private Placement and certain warrants, as well as the replacement warrants issued by the Company on June 10, 2014, the Company agreed to use its commercially reasonable best efforts to have on file with the SEC, by September 11, 2014 and at the Company’s sole expense, a registration statement to permit the public resale of 4,115,966 shares of Company common stock and 3,320,501 shares of common stock underlying warrants (collectively, the “Registrable Securities”). In the event such registration statement includes securities to be offered and sold by the Company in a fully underwritten primary public offering pursuant to an effective registration under the Securities Act of 1933, as amended (the “Securities Act”), and the Company is advised in good faith by any managing underwriter of securities being offered pursuant to such registration statement that the number of Registrable Securities proposed to be sold in such offering is greater than the number of such securities which can be included in such offering without materially adversely affecting such offering, the Company will include in such registration the following securities in the following order of priority: (i) any securities the Company proposes to sell, and (ii) the Registrable Securities, with any reductions in the number of Registrable Securities actually included in such registration to be allocated on a pro rata basis among the holders thereof. The registration rights described above apply until all Registrable Securities have been sold pursuant to Rule 144 under the Securities Act or may be sold without registration in reliance on Rule 144 under the Securities Act without limitation as to volume and without the requirement of any notice filing. If the shares of common stock underlying these warrants to purchase 3,320,501 shares are not registered for resale at the time of exercise, and the registration rights described above then apply with respect to the holder of such warrants, such holder may exercise such warrants on a cashless basis. In such a cashless exercise of all the shares covered by the warrant, the warrant holder would receive a number of shares equal to the quotient of (i) the difference between the fair market value of the common stock, as defined, and the $3.50 exercise price, as adjusted, multiplied by the number of shares exercisable under the warrant, divided by (ii) the fair market value of the common stock, as defined. The Company has not yet filed a registration statement with respect to the resale of the Registrable Securities. The Company believes that it has used commercially reasonable efforts to file a registration statement with respect to the resale of Registrable Securities. Korean Private Placement — On September 12, 2016, the Company entered into Letter of Agreement with KPM and Hanil, both Korean-based public companies whose shares are listed on KOSDAQ, a trading board of Korea Exchange in South Korea. In the Letter of Agreement, the parties agreed that KPM and Hanil would purchase $17.0 million and $3.0 million, respectively, of shares of the Company’s common stock at a price of $4.50 per share. In exchange, the Company agreed to invest $13.0 million and $1.0 million in future capital increases by KPM and Hanil, respectively, at prices based upon the trading prices of KPM and Hanil shares on KOSDAQ. In connection with the Letter of Agreement, KPM and Hanil entered into the Company’s standard form subscription agreement with respect to their purchase of shares which contains customary representations and warranties of the parties. On September 29, 2016, KPM and Hanil purchased from the Company 3,777,778 shares and 666,667 shares, respectively, of common stock at a price of $4.50 a share for $17 million and $3 million, respectively, or a total of $20.0 million. The Company recognized $720,000 as a reduction to its additional paid-in-capital for fees and commissions payable by the Company in connection with the transaction. Pursuant to the terms of the Letter of Agreement dated September 12, 2016, the Company invested $13.0 million and $1.0 million in capital increases by KPM and Hanil, respectively, at $15.32 and $3.68, respectively, per capital share.

COMMITMENTS AND CONTINGENCIES

COMMITMENTS AND CONTINGENCIES	9 Months Ended
	Sep. 30, 2018
Commitments And Contingencies Disclosure [Abstract]
COMMITMENTS AND CONTINGENCIES	NOTE 8 — COMMITMENTS AND CONTINGENCIES Operating leases — The Company leases its office space under operating leases with unrelated entities. The Company has opened its New York office in February 2018 to support a sales team focused on commercial sales for Endari. The rent expense during the three months ended September 30, 2018 and 2017 amounted to $190,903 and $134,585, respectively. The rent expense during the nine months ended September 30, 2018 and 2017 amounted to $493,312 and $427,687, respectively. Future minimum lease payments under the agreements are as follows as of September 30, 2018: Year Amount 2018 (three months) $ 177,959 2019 722,092 2020 637,306 2021 626,545 2022 646,047 Thereafter 777,344 Total $ 3,587,293 Management Control Acquisition Agreement — On June 12, 2017, the Company entered into a Management Control Acquisition Agreement (the “MCAA”) with Telcon Holdings, Inc. (“Telcon Holdings”), a Korean corporation, and Telcon Inc. (“Telcon”), a Korean-based public company whose shares are listed on KOSDAQ, a trading board of Korea Exchange in South Korea. In accordance with the MCAA, the Company invested ₩36.0 billion KRW (approximately $31.8 million USD) to purchase 6,643,559 shares of Telcon’s common stock shares at a purchase price of ₩5,419 KRW (approximately $4.79 USD) per share. Upon consummation of the MCAA, the Company became Telcon’s largest shareholder owning approximately 10.3% of Telcon’s outstanding common stock shares and received representation on its board of directors. The MCAA was amended in certain respect and supplemented by an Agreement, dated as of September 29, 2017, among the parties. Pursuant to the September 2017 Agreement, among other things, Telcon purchased 4,444,445 Emmaus shares from KPM and Hanil at a price of $6.60 per share. On July 2, 2018, we entered into an Additional Agreement with Evercore Investment Holdings Co., Ltd. (formerly Telcon Holdings Co., Ltd.), (“Evercore”), and Telcon RF Pharmaceutical Inc. (formerly Telcon Inc.), (“Telcon”). In the Additional Agreement, we agreed to use the proceeds from any sales of our KPM shares to repurchase Emmaus shares from Telcon at a price of $7.60 a share, subject to certain exceptions, and Telcon granted us the right to purchase from Telcon all or a portion of its Emmaus shares at a price of $7.60 a share until October 31, 2018 and at a price to be agreed upon after October 31, 2018. Telcon also granted us under the Additional Agreement a right of first refusal until June 30, 2019 to purchase any Emmaus shares that Telcon may wish to sell. In connection with the MCAA, on June 15, 2017, Emmaus and Telcon entered into exclusive distribution agreements for the distribution of L-glutamine powder for diverticulosis treatment for the South Korea, Japan and China Territories, with the intention to add the Australia territory. In the Additional Agreement, the parties agreed to dispense with a distribution agreement for Australia, and that the parties have no liabilities or obligations with respect to the intended Australia distribution, including any related liabilities and obligations under the September 2017 Agreement. The Additional Agreement provides for specified damages in the event of a breach of the Additional Agreement by any party. API Supply Agreement — On June 12, 2017, the Company entered into an API Supply Agreement (the “API Agreement”) with Telcon pursuant to which Telcon paid the Company approximately ₩36.0 billion KRW (approximately $31.8 million USD) in consideration of the right to supply 25% of the Company’s requirements for bulk containers of PGLG for a fifteen-year term. Due to unforeseen circumstances, the Company and Telcon held new discussions to re-negotiate certain terms of the API Agreement. The Company and Telcon made significant changes to critical terms of the API Agreement, which resulted in the Company and Telcon signing a Raw Material Supply Agreement (“Revised API Agreement”) on July 12, 2017. The Revised API Agreement is effective for a term of five years with 10 one-year renewal periods for a maximum of 15 years and the agreement will automatically renew unless terminated by either party in writing. The Revised API Agreement does not include yearly purchase commitments or margin guarantees, but revises the API Agreement such that a unit price is established for 940,000 kilograms of PGLG at $50 USD per kilogram for a total of $47.0 million over the 15 years. The Revised API Supply Agreement is silent on yearly purchase commitments and margin guarantees on purchases of $5.0 million and $2.5 million, respectively. The raw materials purchased from Telcon are measured at net realizable value while the excess is recorded against the deferred Trade Discount.

RELATED PARTY TRANSACTIONS

RELATED PARTY TRANSACTIONS	9 Months Ended
	Sep. 30, 2018
Related Party Transactions [Abstract]
RELATED PARTY TRANSACTIONS	NOTE 9 — RELATED PARTY TRANSACTIONS The following table sets forth information relating to our loans from related persons outstanding as of the date hereof or at any time during the nine months ended September 30, 2018: Class Lender Interest Rate Date of Loan Term of Loan Principal Amount Outstanding at September 30, 2018 Highest Principal Outstanding Amount of Principal Repaid or Converted into Stock Amount of Interest Paid Conversion Rate Shares Underlying Notes September 30, 2018 Current, Promissory note payable to related parties: Masaharu & Emiko Osato (3) 11% 12/29/2015 Due on Demand — 300,000 300,000 76,036 — — Masaharu & Emiko Osato (3) 11% 2/25/2016 Due on Demand — 400,000 400,000 94,389 — — Lan T. Tran (2) 10% 4/29/2016 Due on Demand 20,000 20,000 — — — — Hope Hospice (1) 10% 6/3/2016 Due on Demand 250,000 250,000 — — — — Lan T. Tran (2) 10% 2/9/2017 Due on Demand 12,000 12,000 — — — — Yutaka Niihara (2)(3) 10% 9/14/2017 Due on Demand 903,751 903,751 — — — — Lan T. Tran (2) 10% 2/10/2018 Due on Demand 159,222 159,222 — — — — Subtotal $ 1,344,973 $ 2,044,973 $ 700,000 $ 170,425 Current, Convertible notes payable to related parties: Yasushi Nagasaki (2) 10% 6/29/2012 Due on Demand $ 200,000 $ 388,800 $ 188,800 $ - $ 3.30 71,127 Yutaka & Soomi Niihara (2)(3) 10% 11/16/2015 2 years 200,000 200,000 — — $ 4.50 56,109 Subtotal $ 400,000 $ 588,800 $ 188,800 $ - 127,236 Non-Current, Convertible notes payable to related parties: Wei Peu Zen (3) 10% 11/6/2017 2 years 5,000,000 5,000,000 — 250,000 $ 10.00 507,465 Profit Preview Int'l Group, Ltd. (4) 10% 2/1/2018 2 years 4,037,000 4,037,000 — 201,850 $ 10.00 420,290 Profit Preview Int'l Group, Ltd. (4) 10% 3/21/2018 2 years 5,363,000 5,363,000 — 268,150 $ 10.00 551,287 Subtotal $ 14,400,000 $ 14,400,000 $ — $ 720,000 1,479,042 Total $ 16,144,973 $ 17,033,773 $ 888,800 $ 890,425 1,606,278 (1) Dr. Niihara, a Director and Chief Executive Officer of the Company, is also the Chief Executive Officer of Hope Hospice. (2) Officer. (3) Director. (4) Mr. Zen, a Director, is the sole owner of Profit Preview Int'l Group, Ltd. The following table sets forth information relating to our loans from related persons outstanding as of the date hereof or at any time during the year ended December 31, 2017: Class Lender Interest Rate Date of Loan Term of Loan Principal Amount Outstanding at December 31, 2017 Highest Principal Outstanding Amount of Principal Repaid or Converted into Stock Amount of Interest Paid Conversion Rate Shares Underlying Notes December 31, 2017 Current, Promissory note payable to related parties: Hope Hospice (1) 8% 1/17/2012 Due on Demand $ — $ 200,000 $ 200,000 $ 7,331 — — Hope Hospice (1) 8% 6/14/2012 Due on Demand — 200,000 200,000 14,762 — — Hope Hospice (1) 8% 6/21/2012 Due on Demand — 100,000 100,000 7,249 — — Hope Hospice (1) 8% 2/11/2013 Due on Demand — 50,000 50,000 1,559 — — Hope Hospice (1) 10% 1/7/2015 Due on Demand — 100,000 100,000 28,630 — — IRA Service Trust Co. FBO Peter B. Ludlum (2) 10% 2/20/2015 Due on Demand 10,000 10,000 — — — — Masaharu & Emiko Osato (3) 11% 12/29/2015 Due on Demand 300,000 300,000 — — — — Yutaka Niihara (2)(3) 10% 5/21/2015 Due on Demand — 826,105 94,339 61,829 — — Lan T. Tran (2) 11% 2/10/2016 Due on Demand 130,510 130,510 — — — — Masaharu & Emiko Osato (3) 11% 2/25/2016 Due on Demand 400,000 400,000 — — — — Hope Hospice (1) 10% 4/4/2016 Due on Demand — 50,000 50,000 8,110 — — Lan T. Tran (2) 10% 4/29/2016 Due on Demand 20,000 20,000 — — — — IRA Service Trust Co. FBO Peter B. Ludlum (2) 10% 5/5/2016 Due on Demand 10,000 10,000 — — — — Hope Hospice (1) 10% 6/3/2016 Due on Demand 250,000 250,000 — — — — Lan T. Tran (2) 10% 2/9/2017 Due on Demand 12,000 12,000 — — — — Yutaka Niihara (2)(3) 10% 9/14/2017 Due on Demand 903,751 903,751 — — — — Subtotal $ 2,036,261 $ 3,562,366 $ 794,339 $ 129,470 — Current, Convertible notes payable to related parties: Yasushi Nagasaki (2) 10% 6/29/2012 Due on Demand $ 200,000 $ 388,800 $ 188,800 $ 57,886 $ 3.30 68,122 Charles & Kimxa Stark (2) 10% 10/1/2015 2 years — 20,000 20,000 4,405 $ 4.50 — Yutaka & Soomi Niihara (2)(3) 10% 11/16/2015 2 years 200,000 200,000 — — $ 4.50 53,905 Subtotal $ 400,000 $ 608,800 $ 208,800 $ 62,291 122,027 Total $ 2,436,261 $ 4,171,166 $ 1,003,139 $ 191,761 122,027 (1) Dr. Niihara, a Director and Chief Executive Officer of the Company, is also the Chief Executive Officer of Hope Hospice. (2) Officer (3) Director 1

GEOGRAPHIC INFORMATION

GEOGRAPHIC INFORMATION	9 Months Ended
	Sep. 30, 2018
Segment Reporting [Abstract]
GEOGRAPHIC INFORMATION	NOTE 10 — GEOGRAPHIC INFORMATION For the nine months ended September 30, 2018 and 2017, the Company earned revenue from countries as outlined in the table below: Country Revenue for the Nine Months Ended September 30, 2018 % of Total Revenue for the Nine Months Ended September 30, 2018 Revenue for the Nine Months Ended September 30, 2017 % of Total Revenue for the Nine Months Ended September 30, 2017 United States $ 7,669,989 93.1 % $ 66,545 19.2 % Japan 128,644 1.6 % 119,033 32.5 % Taiwan 137,821 1.7 % 180,854 49.4 % France 233,220 2.8 % — 0.0 % Other 64,983 0.8 % — — For the three months ended September 30, 2018 and 2017, the Company earned revenue from countries as outlined in the table below: Country Revenue for the Three Months Ended September 30, 2018 % of Total Revenue for the Three Months Ended September 30, 2018 Revenue for the Three Months Ended September 30, 2017 % of Total Revenue for the Three Months Ended September 30, 2017 United States $ 4,697,135 96.2 % $ 25,042 17.8 % Japan 40,705 0.9 % 48,185 34.4 % Taiwan 0.0 % 67,087 47.8 % France 89,167 1.8 % — 0.0 % Saudi Arabia 55,239 1.1 % — 0.0 % The Company did not have any significant currency translation or foreign transaction adjustments during the nine months ended September 30, 2018 or 2017.

SUBSEQUENT EVENTS

SUBSEQUENT EVENTS	9 Months Ended
	Sep. 30, 2018
Subsequent Events [Abstract]
SUBSEQUENT EVENTS	NOTE 11 — SUBSEQUENT EVENTS Subsequent to September 30, 2018, the Company issued the following: Principal Amounts Annual Interest Rate Term Conversion Price Senior Secured Debentures $ 12,200,000 10.00% 18 Months N/A In October 2018, the Company sold and issued $12.2 million principal amount of debentures and warrants to purchase an aggregate of up to 1,220,000 shares of the Company common stock. The debentures bear interest at the rate of 10% per annum, payable monthly commencing November 1, 2018, and will mature on April 21, 2020. The Company will be obliged to redeem $1,000,000 principal amount of the debentures monthly, commencing in May 2019, and to redeem the debentures in full upon a “subsequent financing” of at least of $20 million, subject to certain exceptions, or in the “event of default” (as defined). The Company’s obligations under the debentures are secured by a security interest in substantially all of our assets, except for certain pledged marketable securities and are guaranteed by the U.S. subsidiaries, Emmaus Medical, Inc. and Newfield Nutrition Corporation. The common stock purchase warrants are exercisable for five years beginning April 22, 2019 at an initial exercise price of $11.30 per share, which will be subject to reduction if we become a listed company or our common stock becomes quoted on a trading market based upon the public offering price or “VWAP” of the Company common stock. The exercise price also will be subject to adjustment in certain other customary circumstances. T.R. Winston & Company, LLC acted as placement agent in connection with the sale of the debentures and warrants pursuant to an amended and restated fee agreement with us dated October 1, 2018. In accordance with the fee agreement, the Company paid T.R. Winston a cash fee equal to 5% of the gross proceeds received from the purchasers granted T.R. Winston warrants to purchase up to 120,000 shares of the Company common stock on the same terms as the common stock purchase warrants sold to the purchasers and reimbursed T.R. Winston for certain legal fees and expenses. On October 9, 2018, the Company entered into a loan agreement dated October 3, 2018 with EJ Holding, Inc., a Japanese corporation, under which the Company made a long-term, unsecured loan to EJ Holdings, Inc. in the amount of 1.5 billion Japanese Yen, or approximately US$13.2 million. EJ Holdings, Inc. is 40% owned by the Company. The loan bears interest at a nominal rate payable annually on September 30 of each year, and will be due and payable in full on September 30, 2028, unless previously paid. The loan may be prepaid at any time without premium or penalty. EJ Holdings, Inc. has entered into an acquisition agreement with Kyowa Hakko Bio Co. Ltd., a subsidiary of Kyowa Hakko Kirin Co., Ltd., to purchase Kyowa Hakko Bio Co. Ltd.’s manufacturing facility in Ube, Japan. The proceeds of the Company’s loan to EJ Holdings, Inc. will be used to fund the acquisition, which is expected to occur in or about December 2019, subject to regulatory approval and other closing conditions.

SUMMARY OF SIGNIFICANT ACCOUN_2

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)	9 Months Ended
	Sep. 30, 2018
Accounting Policies [Abstract]
Revenues	Revenues – Effective January 1, 2018, the Company adopted Accounting Standard codification (“ASC”) Topic 606, Revenue from Contracts with Customers using the modified retrospective transition methods. The adoption of ASC 606 did not have a material impact on the measurement or on the recognition of revenue of contracts for which all revenue had not been recognized as of January 1, 2018, therefore no cumulative adjustment has been made to the opening balance of accumulated deficit at the beginning of 2018. The comparative information has not been restated and continues to be reported under the accounting standards in effect for the periods presented. Since January 2018, the Company has generated revenues through the sale of Endari as a treatment for sickle cell disease (“SCD”). The Company also generates revenues to a much lesser extent from NutreStore L-glutamine powder, as well as AminoPure, a nutritional supplement. Revenues from Endari product sales are recognized upon transfer to our distributors, which are customers of the Company, when they obtain control of our products. These distributors subsequently resell our products to specialty pharmacy providers, health care providers, hospitals, patients and clinics. In addition to distribution agreements with these distributors, the Company enters into arrangements with specialty pharmacy providers, in-office dispensing providers, group purchasing organizations, and government entities that provide for government-mandated and/or privately-negotiated rebates, chargebacks and discounts with respect to the purchase of our products. These various discounts, rebates, and charge-backs are referred to as “variable consideration.” Revenues from product sales are recorded net of these variable considerations. Prior to recognizing revenues, the Company’s management forecasts and estimates variable consideration. Amounts of variable consideration are included in the transaction price to the extent that it is probable that a significant reversal in the amount of cumulative revenues recognized will not occur when the uncertainty associated with the variable consideration is subsequently resolved. Up until June 30, 2018, the Company recognized Endari sales revenues based upon the script data reports on shipments to patients as the Company did not have sufficient historical information to reliably forecast and estimate variable consideration and product returns. During the three months ended September 30, 2018, the Company obtained additional information based on new contracts signed with major distributors and pharmacies, knowledge of our reimbursement payor mix, as well as improved visibility as to the relatively fast turnover of Endari inventory at the distributor level. As such, the new information obtained in the three months ended September 30, 2018 provided the Company with the ability to better forecast and estimate the expected variable consideration related to sales to the distributors, which are customers of the Company, as well as establishing the expectation of a low level of product returns. The gross sales of Endari to these customers were $1.3 million, $3.8 million and $5.5 million for the three month periods ended March 31, June 30 and September 30 of 2018, respectively. The net revenues for Endari reported for these periods were $0.7 million, $2.3 million and $4.7 million for the three month periods ended March 31, June 30 and September 30 of 2018, respectively. The effect of being better able to forecast and estimate the expected variable consideration permitted the Company, in the three months ended September 30, 2018, to recognize $0.7 million in revenues that had been deferred in prior periods when the Company did not have sufficient historical information to reliably forecast and estimate variable consideration and product returns. Provisions for returns and other adjustments are provided for in the period in which the related revenues are recorded. Actual amounts of consideration ultimately received may differ from the management estimates. If actual results in the future vary from the estimates, the management will adjust these estimates, which would affect net product revenues in the period such variances become known. The following are our significant categories of sales discounts and allowances: Sales Discounts: The Company provides its customers prompt payment discounts that are explicitly stated in its contracts and are recorded as a reduction of revenues in the period the revenues are recognized. Product Returns: The Company offers its distributors a right to return product purchased directly from the Company, which is principally based upon (i) overstocks, (ii) inactive product or non-moving product due to market conditions, and (iii) expired products. Product return allowances are estimated and recorded at the time of sale. Government Rebates: The Company is subject to discount obligations under state Medicaid programs and the Medicare prescription drug coverage gap program. The Company’s management estimates Medicaid and Medicare prescription drug coverage gap rebates based upon a range of possible outcomes that are probability-weighted for the estimated payor mix. These reserves are recorded in the same period the related revenues are recognized, resulting in a reduction of product revenues and the establishment of a current liability that is included as an accrued liability in our balance sheet. The liability for these rebates consists primarily of estimates of claims expected to be received in future periods related to recognized revenues. Chargebacks and Discounts: Chargebacks for fees and discounts represent the estimated obligations resulting from contractual commitments to sell products to certain specialty pharmacy providers, in-office dispensing providers, group purchasing organizations, and government entities at prices lower than the list prices charged to distributors. The distributors charge the Company for the difference between what they pay for the products and the Company’s contracted selling price to these specialty pharmacy providers, in-office dispensing providers, group purchasing organizations, and government entities. These reserves are established in the same period that the related revenues are recognized, resulting in a reduction of revenues. Chargeback amounts are generally determined at the time of resale of products by the distributors.
Inventories	Inventories — All of the raw material purchased during the nine months ended September 30, 2018 were from two vendors and for the year ended December 31, 2017 were from one vendor. The below table presents inventory by category: Inventories by category September 30, 2018 December 31, 2017 Raw materials and components $ 184,126 $ — Work-in-process 924,275 124,801 Finished goods 2,238,828 500,498 Total $ 3,347,229 $ 625,299
Advertising cost	Advertising cost — Advertising costs are expensed as incurred. Advertising costs for the three months ended September 30, 2018 and 2017 were $16,750 and $18,201, respectively. Advertising costs for the nine months ended September 30, 2018 and 2017 were $76,654 and $35,399, respectively.
Marketable securities	Marketable securities — The Company’s marketable securities consist of the following securities; (a) 39,250 shares of capital stock of CellSeed, Inc. (“CellSeed”) those that remain of the 147,100 shares acquired in January 2009 for ¥100,028,000 Japanese Yen (JPY) (equivalent to $1.1 million USD), at ¥680 JPY per share; (b) 849,744 shares of capital stock of KPM Tech Co., Ltd. (“KPM”) which were acquired in October 2016 for ₩14,318,186,400 South Korean Won (KRW) (equivalent to $13.0 million USD) at ₩16,850 KRW per share; (c) 271,950 shares of capital stock of Hanil Vacuum Co., Ltd. (“Hanil”) which were acquired in October 2016 for ₩1,101,397,500 KRW (equivalent to $1.0 million USD) at ₩4,050 KRW per share; and (d) 6,643,559 shares of capital stock of Telcon, Inc. (“Telcon”) which were acquired in July 2017 for ₩36,001,446,221 KRW (equivalent to $31.8 million USD) at ₩5,419 KRW per share. As of September 30, 2018 and December 31, 2017, the closing prices per CellSeed share on the Tokyo Stock Exchange were ¥1,001 ($8.80 USD) and ¥462 JPY ($4.10 USD), respectively, and the closing prices per Telcon share on the Korean Securities Dealers Automated Quotations (“KOSDAQ”) were ₩10,300 ($9.27 USD) and ₩14,900 KRW ($13.95 USD), respectively. As of December 31, 2017, the closing price per KPM share on KOSDAQ was ₩1,625 KRW ($1.52 USD) and the closing price per Hanil share on KOSDAQ was ₩2,830 KRW ($2.65 USD). During the three months ended September 30, 2018, the Company sold all of its KPM and Hanil shares. As of September 30, 2018, and December 31, 2017, 39,250 shares of CellSeed common stock were pledged to secure a $300,000 convertible note of the Company issued to Mitsubishi UFJ Capital III Limited Partnership that is due on demand and were classified as current assets, as marketable securities, pledged to creditor. In addition, as of September 30, 2018 and December 31, 2017 6,643,559 shares of Telcon were pledged to secure the API Supply Agreement (see Note 8) in which Emmaus received $31,800,000 related to a trade advance discount. These shares were classified as current assets, as investment in marketable securities
Prepaid expenses and other current assets	Prepaid expenses and other current assets — Prepaid expenses and other current assets consisted of the following at September 30, 2018 and December 31, 2017: September 30, 2018 December 31, 2017 Prepaid insurance $ 72,510 $ 132,387 Other prepaid expenses and current assets 246,633 157,984 Total prepaid expenses $ 319,143 $ 290,371
Other Non-Current Liabilities	Other long-term liabilities — Other long-term liabilities consisted of the following at September 30, 2018 and December 31, 2017: September 30, 2018 December 31, 2017 Trade discount $ 29,531,500 $ 31,841,500 Unearned revenue 10,000,000 5,000,000 Other long-term liabilities — 10,790 Total other long-term liabilities $ 39,531,500 $ 36,852,290 The Company has entered into an API Supply Agreement (the “API Agreement”) with Telcon pursuant to which Telcon advanced to the Company approximately ₩36.0 billion KRW (approximately $31.8 million USD) as a trade discount to supply 25% of the Company’s requirements for bulk containers of pharmaceutical grade L-glutamine (“PGLG”) for a term of five years, with 10 one-year renewal terms. The agreement will automatically renew unless terminated by either party in writing. The agreement does not include yearly purchase commitments or margin guarantees. The advance trade discount will be applied against purchases made by the Company from Telcon over the life of the agreement.
Fair value measurements	Fair value measurements — The following table presents the activity for those items measured at fair value on a recurring basis using Level 3 inputs during the nine months ended September 30, 2018 and the year ended December 31, 2017: Nine Months Ended Year Ended Warrant Derivative Liabilities—Stock Purchase Warrants September 30, 2018 December 31, 2017 Balance, beginning of period $ 26,377,000 $ 10,600,000 Repurchased (6,186,000 ) — Change in fair value included in the statement of comprehensive income (loss) (20,191,000 ) 15,777,000 Balance, end of period $ — $ 26,377,000 The following table presents warrants issued to GPB Debt Holdings II, LLC as described in Note 7 measured at fair value as of September 30, 2018: Nine Months Ended September 30, 2018 Year Ended December 31, 2017 Liability Instrument—GPB Warrants Embedded Conversion Option Warrants Embedded Conversion Option Balance, beginning of period $ 1,882,000 $ 1,289,000 $ — $ — Fair value at issuance date — — 1,882,000 1,289,000 Change in fair value included in the statement of comprehensive income (loss) (160,000 ) (466,000 ) — — Extinguished upon debt repayment — (823,000 ) — — Balance, end of period $ 1,722,000 $ — $ 1,882,000 $ 1,289,000 The value of warrant derivative liabilities and the change in fair value of the warrant derivative liabilities were determined using a Binomial Monte-Carlo Cliquet (aka “Ratchet”) Option Pricing Model. The model is similar to traditional Black-Scholes-type option pricing models, except that the exercise price resets at certain dates in the future. The value as of the dates set forth in the table below, was based on upon following assumptions: September 30, 2018 December 31, 2017 Stock price $ 11.10 $ 11.40 Risk‑free interest rate 2.92 % 2.20 % Expected volatility (peer group) 70.00 % 70.00 % Expected life (in years) 4.25 5.00 Expected dividend yield — — Number outstanding 240,764 240,764 Balance, end of period: Warrant derivative liabilities (long-term) $ 1,722,000 $ 1,882,000
Debt and related party debt	Debt and related party debt — The following table presents the effective interest rates on loans originated and refinanced in the respective periods that either had a beneficial conversion feature or an attached warrant: Type of Loan Term of Loan Stated Annual Interest Original Loan Principal Amount Conversion Rate Beneficial Conversion Discount Amount Warrants Issued with Notes Exercise Price Warrant FMV Discount Amount Effective Interest Rate Including Discounts 2017 convertible notes payable Due on demand - 3 years 10% - 13.5% $ 36,113,296 $3.50 - $10.31 $ 11,678,725 240,764 $ 10.80 $ 1,882,000 10% - 110% 2018 convertible notes payable Due on demand - 2 years 6% - 10% 26,501,808 $3.50 - $10.00 10,218,609 — — — 19% - 110% $ 62,615,104 $ 21,897,334 240,764 $ 1,882,000 Related party notes are disclosed as separate line items in the Company’s consolidated balance sheets.
Net loss per share	Net loss per share — As of September 30, 2018 and 2017, respectively, potentially dilutive securities exercisable or convertible into 15,286,940 and 15,617,245 shares of Company common stock were outstanding. No potentially dilutive securities were included in the calculation of diluted net loss per share since their effect would be anti-dilutive for all periods presented.
Recent accounting pronouncements	Recent accounting pronouncements —In January 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2016-01, Recognition and Measurement of Financial Assets and Financial Liabilities . The amendments applicable to the Company in this Update (1) supersede the guidance to classify equity securities, except equity method securities, with readily determinable fair values into trading or available-for-sale categories and require equity securities to be measured at fair value with changes in the fair value recognized through net income, (2) allow equity investments that do not have readily determinable fair values to be remeasured at fair value either upon the occurrence of an observable price change or upon identification of an impairment, (3) require assessment for impairment of equity investments without readily determinable fair values qualitatively at each reporting period, (4) eliminate the requirement to disclose the methods and significant assumptions used in calculating the fair value of financial instruments required to be disclosed for financial instruments measured at amortized cost on the balance sheet, (5) require public business entities to use the exit price notion when measuring the fair value of financial instruments for disclosure purposes, (6) require separate presentation of financial assets and financial liabilities by measurement category and form of financial asset (that is, securities or loans and receivables) on the balance sheet or the accompanying notes to the financial statements, (7) clarify that an entity should evaluate the need for a valuation allowance on a deferred tax asset related to available-for-sale securities in combination with the entity’s other deferred tax assets. This Update was effective beginning January 1, 2018 and the Company is now recognizing any changes in the fair value of certain equity investments in net income as prescribed by the new standard rather than in other comprehensive income. The Company recognized a cumulative effect adjustment to increase the opening balance of retained earnings as of January 1, 2018 by $41.4 million, net of $12.3 million income tax benefit. Refer to Note 4 for additional disclosures required by this ASU. In February 2016, the FASB issued ASU No. 2016-02, Leases Targeted Improvements In April 2016, the FASB issued ASU 2016-10, Revenue from Contracts with Customers (Topic 606): Identifying Performance Obligations and Licensing In July 2017, the FASB issued ASU No. 2017-11, Earnings Per Share (Topic 260) Distinguishing Liabilities from Equity (Topic 480) Derivatives and Hedging (Topic 815): I. Accounting for Certain Financial Instruments with Down Round Features, II. Replacement of the Indefinite Deferral for Mandatorily Redeemable Financial Instruments of Certain Nonpublic Entities and Certain Mandatorily Redeemable Noncontrolling Interests with a Scope Exception. In February 2018, the FASB issued ASU No. 2018-02, Income Statement – Reporting Comprehensive Income (Topic 220): Reclassification of Certain Tax Effects from Accumulated Other Comprehensive Income In February 2018, the FASB issued ASU No. 2018-03, Technical Corrections and Improvements to Financial Instruments—Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities Fair Value Measurement Derivatives and Hedging— Embedded Derivatives Financial Instruments— Overall In June 2018, the FASB issued ASU No. 2018-07, Compensation – Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting In August 2018, the FASB issued ASU No. 2018-13, Fair Value Measurement (Topic 820): Disclosure Framework – Changes to the Disclosure Requirements for Fair Value Measurement accompanying footnote disclosures In August 2018, the FASB issued ASU 2018-15, Intangibles – Goodwill and Other – Internal-Use Software (Subtopic 350-40) Customer’s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That is a Service Contract

SUMMARY OF SIGNIFICANT ACCOUN_3

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)	9 Months Ended
	Sep. 30, 2018
Accounting Policies [Abstract]
Schedule of inventory	The below table presents inventory by category: Inventories by category September 30, 2018 December 31, 2017 Raw materials and components $ 184,126 $ — Work-in-process 924,275 124,801 Finished goods 2,238,828 500,498 Total $ 3,347,229 $ 625,299
Schedule of prepaid expenses and other current assets	Prepaid expenses and other current assets consisted of the following at September 30, 2018 and December 31, 2017: September 30, 2018 December 31, 2017 Prepaid insurance $ 72,510 $ 132,387 Other prepaid expenses and current assets 246,633 157,984 Total prepaid expenses $ 319,143 $ 290,371
Schedule of other long-term liabilities	Other long-term liabilities consisted of the following at September 30, 2018 and December 31, 2017: September 30, 2018 December 31, 2017 Trade discount $ 29,531,500 $ 31,841,500 Unearned revenue 10,000,000 5,000,000 Other long-term liabilities — 10,790 Total other long-term liabilities $ 39,531,500 $ 36,852,290
Schedule of changes in fair value of liabilities	Fair value measurements — The following table presents the activity for those items measured at fair value on a recurring basis using Level 3 inputs during the nine months ended September 30, 2018 and the year ended December 31, 2017: Nine Months Ended Year Ended Warrant Derivative Liabilities—Stock Purchase Warrants September 30, 2018 December 31, 2017 Balance, beginning of period $ 26,377,000 $ 10,600,000 Repurchased (6,186,000 ) — Change in fair value included in the statement of comprehensive income (loss) (20,191,000 ) 15,777,000 Balance, end of period $ — $ 26,377,000
Schedule of warrants issued to GPB Debt Holdings II, LLC	The following table presents warrants issued to GPB Debt Holdings II, LLC as described in Note 7 measured at fair value as of September 30, 2018: Nine Months Ended September 30, 2018 Year Ended December 31, 2017 Liability Instrument—GPB Warrants Embedded Conversion Option Warrants Embedded Conversion Option Balance, beginning of period $ 1,882,000 $ 1,289,000 $ — $ — Fair value at issuance date — — 1,882,000 1,289,000 Change in fair value included in the statement of comprehensive income (loss) (160,000 ) (466,000 ) — — Extinguished upon debt repayment — (823,000 ) — — Balance, end of period $ 1,722,000 $ — $ 1,882,000 $ 1,289,000
Schedule of assumptions used in the valuation of warrants	The value as of the dates set forth in the table below, was based on upon following assumptions: September 30, 2018 December 31, 2017 Stock price $ 11.10 $ 11.40 Risk‑free interest rate 2.92 % 2.20 % Expected volatility (peer group) 70.00 % 70.00 % Expected life (in years) 4.25 5.00 Expected dividend yield — — Number outstanding 240,764 240,764 Balance, end of period: Warrant derivative liabilities (long-term) $ 1,722,000 $ 1,882,000
Schedule of notes payable with beneficial conversion feature or warrants	The following table presents the effective interest rates on loans originated and refinanced in the respective periods that either had a beneficial conversion feature or an attached warrant: Type of Loan Term of Loan Stated Annual Interest Original Loan Principal Amount Conversion Rate Beneficial Conversion Discount Amount Warrants Issued with Notes Exercise Price Warrant FMV Discount Amount Effective Interest Rate Including Discounts 2017 convertible notes payable Due on demand - 3 years 10% - 13.5% $ 36,113,296 $3.50 - $10.31 $ 11,678,725 240,764 $ 10.80 $ 1,882,000 10% - 110% 2018 convertible notes payable Due on demand - 2 years 6% - 10% 26,501,808 $3.50 - $10.00 10,218,609 — — — 19% - 110% $ 62,615,104 $ 21,897,334 240,764 $ 1,882,000

PROPERTY AND EQUIPMENT (Tables)

PROPERTY AND EQUIPMENT (Tables)	9 Months Ended
	Sep. 30, 2018
Property Plant And Equipment [Abstract]
Schedule of property and equipment	Property and equipment consisted of the following at: September 30, 2018 December 31, 2017 Equipment $ 292,212 $ 225,615 Leasehold improvements 70,249 61,054 Furniture and fixtures 79,001 74,090 Subtotal 441,462 360,759 Less: accumulated depreciation (288,972 ) (255,457 ) Total $ 152,490 $ 105,302

INVESTMENTS (Tables)

INVESTMENTS (Tables)	9 Months Ended
	Sep. 30, 2018
Investments [Abstract]
Schedule of carrying values of equity securities	As of September 30, 2018, the carrying values of our equity securities were included in the following line items in our consolidated balance sheets: At September 30, 2018 Fair Value with Changes Recognized in Income Measurement Alternative - No Readily Determinable Fair Value Marketable securities $ 61,931,302 $ — Other investments — 572,199 Total equity securities $ 61,931,302 $ 572,199
Schedule of net unrealized gains and losses of equity securities	The calculation of net unrealized gains and losses for the period that relate to equity securities still held at September 30, 2018 is as follows: Nine Months Ended September 30, 2018 Net losses recognized during the period related to equity securities $ (31,626,779 ) Less: Net gain (loss) recognized during the period related to equity securities sold during the period (7,560,760 ) Unrealized gain (loss) recognized during the period related to equity securities still held at the end of the period $ (24,066,019 )
Schedule of equity securities	As of December 31, 2017, equity securities consisted of the following: Gross Unrealized Estimated Cost Gains Losses Fair Value Trading securities $ — $ — $ — $ — Available-for-sale securities 46,209,017 60,812,231 (6,958,406 ) 100,062,842 Total equity securities $ 46,209,017 $ 60,812,231 $ (6,958,406 ) $ 100,062,842
Schedule of fair values of equity securities	As of December 31, 2017, the fair values of our equity securities were included in the following line items in our consolidated balance sheets: Available-for-Sale Securities Marketable securities $ 99,997,322 Long-term investment at cost 65,520 Total equity securities $ 100,062,842

ACCOUNTS PAYABLE AND ACCRUED _2

ACCOUNTS PAYABLE AND ACCRUED EXPENSES (Tables)	9 Months Ended
	Sep. 30, 2018
Payables And Accruals [Abstract]
Schedule of accounts payable and accrued expenses	Accounts payable and accrued expenses consisted of the following: September 30, 2018 December 31, 2017 Accounts payable: Regulatory fees $ — $ 715,999 Clinical and regulatory expenses 296,316 116,736 Commercialization consulting fees 8,544 30,000 Manufacturing cost 394,093 217,155 Legal expenses 60,526 87,701 Consulting fees 224,850 147,038 Accounting fees 25,770 67,293 Selling expenses 380,604 35,383 Investor relations and public relations expenses - 45,526 Board member compensation 278,740 11,200 Other vendors 976,095 125,605 Total accounts payable 2,645,538 1,599,636 Accrued interest payable, related parties 506,322 318,120 Accrued interest payable 1,976,563 1,449,154 Accrued expenses: Wages and payroll taxes payable 95,021 1,711,541 Deferred salary 291,667 291,667 Paid vacation payable 251,288 186,978 Other accrued expenses 1,775,627 138,214 Total accrued expenses 2,413,603 2,328,400 Total accounts payable and accrued expenses $ 7,542,026 $ 5,695,310

NOTES PAYABLE (Tables)

NOTES PAYABLE (Tables)	9 Months Ended
	Sep. 30, 2018
Debt Disclosure [Abstract]
Schedule of notes payable	Notes payable consisted of the following at September 30, 2018 and December 31, 2017: Year Issued Interest Rate Range Term of Notes Conversion Price Principal Outstanding September 30, 2018 Discount Amount September 30, 2018 Carrying Amount September 30, 2018 Shares Underlying Notes September 30, 2018 Principal Outstanding December 31, 2017 Discount Amount December 31, 2017 Carrying Amount December 31, 2017 Shares Underlying Notes December 31, 2017 Notes payable 2013 10% Due on demand — $ 879,400 $ — $ 879,400 — $ 887,600 $ — $ 887,600 — 2015 10% Due on demand — 10,000 — 10,000 — — — — — 2016 10% - 11% Due on demand — 843,335 — 843,335 — 833,335 — 833,335 — 2017 11% Due on demand — 2,540,506 — 2,540,506 — 6,150,208 — 6,150,208 — 2018 10% - 11% Due on demand - 18 months — 6,811,000 30,000 6,781,000 — — — — — $ 11,084,241 $ 30,000 $ 11,054,241 — $ 7,871,143 $ — $ 7,871,143 — Current $ 4,384,241 $ — $ 4,384,241 — $ 7,871,143 $ — $ 7,871,143 — Non-current $ 6,700,000 $ 30,000 $ 6,670,000 — $ — $ — $ — — Notes payable - related party 2015 11% Due on demand — — — — — 310,000 — 310,000 — 2016 10% Due on demand — 270,000 — 270,000 — 810,510 — 810,510 — 2017 10% Due on demand — 915,751 — 915,751 — 915,751 — 915,751 — 2018 11% Due on demand — 159,222 — 159,222 — — — — — $ 1,344,973 $ — $ 1,344,973 — $ 2,036,261 $ — $ 2,036,261 — Current $ 1,344,973 $ — $ 1,344,973 — $ 2,036,261 $ — $ 2,036,261 — Non-current $ — $ — $ — — $ — $ — $ — — Convertible notes payable 2011 10% 5 years $ 3.05 $ 300,000 $ — $ 300,000 98,285 $ 300,000 $ — $ 300,000 98,285 2014 10% Due on demand - 2 years $3.05 - $3.60 501,273 — 501,273 176,777 486,878 — 486,878 168,766 2016 10% 1 year - 2 years $3.60 - $4.50 182,495 7,952 174,543 55,983 1,516,329 83,298 1,433,031 441,048 2017 10% Due on demand - 2 years $3.50 - $10.00 5,256,547 947,731 4,308,816 1,441,824 36,113,296 11,232,423 24,880,873 5,357,488 2018 6% - 10% Due on demand - 2 years $3.50 - $10.00 16,522,996 2,411,522 14,111,474 2,983,385 — — — — $ 22,763,311 $ 3,367,205 $ 19,396,106 4,756,254 $ 38,416,503 $ 11,315,721 $ 27,100,782 6,065,587 Current $ 16,256,710 $ 2,119,066 $ 14,137,644 2,119,066 $ 12,860,912 $ 5,835,910 $ 7,025,002 3,449,984 Non-current $ 6,506,601 $ 1,248,139 $ 5,258,462 2,637,188 $ 25,555,591 $ 5,479,811 $ 20,075,780 2,615,603 Convertible notes payable - related party 2012 10% Due on demand $ 3.30 $ 200,000 $ — $ 200,000 71,127 $ 200,000 $ — $ 200,000 68,122 2015 10% 2 years $ 4.50 200,000 — 200,000 56,109 200,000 — 200,000 53,905 2017 10% 2 years $ 10.00 5,000,000 407,292 4,592,708 507,465 — — — — 2018 10% 2 years $ 10.00 9,400,000 1,058,320 8,341,680 971,577 — — — — $ 14,800,000 $ 1,465,612 $ 13,334,388 1,606,278 $ 400,000 $ — $ 400,000 122,027 Current $ 400,000 $ — $ 400,000 127,236 $ 400,000 $ — $ 400,000 122,027 Non-current $ 14,400,000 $ 1,465,612 $ 12,934,388 1,479,042 $ — $ — $ — — Total $ 49,992,525 $ 4,862,817 $ 45,129,708 6,362,532 $ 48,723,907 $ 11,315,721 $ 37,408,186 6,187,614
Schedule of contractual principal payments of notes payable	Contractual principal payments due on notes payable are as follows: 2018 (three months) $ 20,894,505 2019 6,491,419 2020 22,606,601 Total $ 49,992,525
Schedule of fair value assumptions for warrants issued in conjunction with notes	2018 2017 Stock price — $ 11.40 Exercise price — $ 10.80 Term — 5 years Risk‑free interest rate — 2.20 % Expected dividend yield — — Expected volatility — 70.0 %

STOCKHOLDERS' DEFICIT (Tables)

STOCKHOLDERS' DEFICIT (Tables)	9 Months Ended
	Sep. 30, 2018
Stockholders Equity Note [Abstract]
Schedule of outstanding warrants	A summary of outstanding warrants as of September 30, 2018 and December 31, 2017 is presented below: Nine Months Ended Year Ended September 30, 2018 December 31, 2017 Warrants outstanding, beginning of period 5,265,432 5,024,668 Granted 202,000 240,764 Exercised (2,384,817 ) — Cancelled, forfeited and expired (985,684 ) — Warrants outstanding, end of period 2,096,931 5,265,432 A summary of outstanding warrants by year issued and exercise price as of September 30, 2018 is presented below: Outstanding Exercisable Year issued and Exercise Price Number of Warrants Issued Weighted Average Remaining Contractual Life (Years) Weighted Average Exercise Price Total Weighted Average Exercise Price At December 31, 2014 $ 3.50 50,000 0.58 $ 3.50 50,000 $ 3.50 2014 Total 50,000 50,000 At December 31, 2015 $ 4.90 110,417 1.43 $ 4.90 110,417 $ 4.90 2015 Total 110,417 110,417 At December 31, 2016 $ 4.50 118,750 2.75 $ 4.50 118,750 $ 4.50 $ 4.70 75,000 2.59 $ 4.70 75,000 $ 4.70 $ 5.00 1,300,000 2.61 $ 5.00 1,300,000 $ 5.00 2016 Total 1,493,750 1,493,750 At December 31, 2017 $ 10.80 240,764 4.75 $ 10.80 240,764 $ 10.80 2017 Total 240,764 240,764 At September 30, 2018 $ 11.30 202,000 4.86 $ 11.30 202,000 $ 11.30 Grand Total 2,096,931 2,096,931
Schedule of option activity	Summaries of outstanding options as of September 30, 2018 and December 31, 2017 are presented below. September 30, 2018 December 31, 2017 Number of Options Weighted‑ Average Exercise Price Number of Options Weighted‑ Average Exercise Price Options outstanding, beginning of period 6,775,200 $ 4.12 6,955,200 $ 4.10 Granted or deemed issued 357,000 $ 11.28 50,000 $ 11.40 Exercised (170,000 ) $ 4.59 (11,895 ) $ 4.19 Cancelled, forfeited and expired (126,666 ) $ 5.43 (218,105 ) $ 4.98 Options outstanding, end of period 6,835,534 $ 4.46 6,775,200 $ 4.12 Options exercisable, end of period 5,985,823 $ 4.02 5,604,439 $ 3.95 Options available for future grant 2,164,466 2,224,800

COMMITMENTS AND CONTINGENCIES (

COMMITMENTS AND CONTINGENCIES (Tables)	9 Months Ended
	Sep. 30, 2018
Commitments And Contingencies Disclosure [Abstract]
Schedule of future minimum lease payments	Future minimum lease payments under the agreements are as follows as of September 30, 2018: Year Amount 2018 (three months) $ 177,959 2019 722,092 2020 637,306 2021 626,545 2022 646,047 Thereafter 777,344 Total $ 3,587,293

RELATED PARTY TRANSACTIONS (Tab

RELATED PARTY TRANSACTIONS (Tables)	9 Months Ended
	Sep. 30, 2018
Related Party Transactions [Abstract]
Schedule of outstanding loans from related persons	The following table sets forth information relating to our loans from related persons outstanding as of the date hereof or at any time during the nine months ended September 30, 2018: Class Lender Interest Rate Date of Loan Term of Loan Principal Amount Outstanding at September 30, 2018 Highest Principal Outstanding Amount of Principal Repaid or Converted into Stock Amount of Interest Paid Conversion Rate Shares Underlying Notes September 30, 2018 Current, Promissory note payable to related parties: Masaharu & Emiko Osato (3) 11% 12/29/2015 Due on Demand — 300,000 300,000 76,036 — — Masaharu & Emiko Osato (3) 11% 2/25/2016 Due on Demand — 400,000 400,000 94,389 — — Lan T. Tran (2) 10% 4/29/2016 Due on Demand 20,000 20,000 — — — — Hope Hospice (1) 10% 6/3/2016 Due on Demand 250,000 250,000 — — — — Lan T. Tran (2) 10% 2/9/2017 Due on Demand 12,000 12,000 — — — — Yutaka Niihara (2)(3) 10% 9/14/2017 Due on Demand 903,751 903,751 — — — — Lan T. Tran (2) 10% 2/10/2018 Due on Demand 159,222 159,222 — — — — Subtotal $ 1,344,973 $ 2,044,973 $ 700,000 $ 170,425 Current, Convertible notes payable to related parties: Yasushi Nagasaki (2) 10% 6/29/2012 Due on Demand $ 200,000 $ 388,800 $ 188,800 $ - $ 3.30 71,127 Yutaka & Soomi Niihara (2)(3) 10% 11/16/2015 2 years 200,000 200,000 — — $ 4.50 56,109 Subtotal $ 400,000 $ 588,800 $ 188,800 $ - 127,236 Non-Current, Convertible notes payable to related parties: Wei Peu Zen (3) 10% 11/6/2017 2 years 5,000,000 5,000,000 — 250,000 $ 10.00 507,465 Profit Preview Int'l Group, Ltd. (4) 10% 2/1/2018 2 years 4,037,000 4,037,000 — 201,850 $ 10.00 420,290 Profit Preview Int'l Group, Ltd. (4) 10% 3/21/2018 2 years 5,363,000 5,363,000 — 268,150 $ 10.00 551,287 Subtotal $ 14,400,000 $ 14,400,000 $ — $ 720,000 1,479,042 Total $ 16,144,973 $ 17,033,773 $ 888,800 $ 890,425 1,606,278 (1) Dr. Niihara, a Director and Chief Executive Officer of the Company, is also the Chief Executive Officer of Hope Hospice. (2) Officer. (3) Director. (4) Mr. Zen, a Director, is the sole owner of Profit Preview Int'l Group, Ltd. The following table sets forth information relating to our loans from related persons outstanding as of the date hereof or at any time during the year ended December 31, 2017: Class Lender Interest Rate Date of Loan Term of Loan Principal Amount Outstanding at December 31, 2017 Highest Principal Outstanding Amount of Principal Repaid or Converted into Stock Amount of Interest Paid Conversion Rate Shares Underlying Notes December 31, 2017 Current, Promissory note payable to related parties: Hope Hospice (1) 8% 1/17/2012 Due on Demand $ — $ 200,000 $ 200,000 $ 7,331 — — Hope Hospice (1) 8% 6/14/2012 Due on Demand — 200,000 200,000 14,762 — — Hope Hospice (1) 8% 6/21/2012 Due on Demand — 100,000 100,000 7,249 — — Hope Hospice (1) 8% 2/11/2013 Due on Demand — 50,000 50,000 1,559 — — Hope Hospice (1) 10% 1/7/2015 Due on Demand — 100,000 100,000 28,630 — — IRA Service Trust Co. FBO Peter B. Ludlum (2) 10% 2/20/2015 Due on Demand 10,000 10,000 — — — — Masaharu & Emiko Osato (3) 11% 12/29/2015 Due on Demand 300,000 300,000 — — — — Yutaka Niihara (2)(3) 10% 5/21/2015 Due on Demand — 826,105 94,339 61,829 — — Lan T. Tran (2) 11% 2/10/2016 Due on Demand 130,510 130,510 — — — — Masaharu & Emiko Osato (3) 11% 2/25/2016 Due on Demand 400,000 400,000 — — — — Hope Hospice (1) 10% 4/4/2016 Due on Demand — 50,000 50,000 8,110 — — Lan T. Tran (2) 10% 4/29/2016 Due on Demand 20,000 20,000 — — — — IRA Service Trust Co. FBO Peter B. Ludlum (2) 10% 5/5/2016 Due on Demand 10,000 10,000 — — — — Hope Hospice (1) 10% 6/3/2016 Due on Demand 250,000 250,000 — — — — Lan T. Tran (2) 10% 2/9/2017 Due on Demand 12,000 12,000 — — — — Yutaka Niihara (2)(3) 10% 9/14/2017 Due on Demand 903,751 903,751 — — — — Subtotal $ 2,036,261 $ 3,562,366 $ 794,339 $ 129,470 — Current, Convertible notes payable to related parties: Yasushi Nagasaki (2) 10% 6/29/2012 Due on Demand $ 200,000 $ 388,800 $ 188,800 $ 57,886 $ 3.30 68,122 Charles & Kimxa Stark (2) 10% 10/1/2015 2 years — 20,000 20,000 4,405 $ 4.50 — Yutaka & Soomi Niihara (2)(3) 10% 11/16/2015 2 years 200,000 200,000 — — $ 4.50 53,905 Subtotal $ 400,000 $ 608,800 $ 208,800 $ 62,291 122,027 Total $ 2,436,261 $ 4,171,166 $ 1,003,139 $ 191,761 122,027 (1) Dr. Niihara, a Director and Chief Executive Officer of the Company, is also the Chief Executive Officer of Hope Hospice. (2) Officer (3) Director 1

GEOGRAPHIC INFORMATION (Tables)

GEOGRAPHIC INFORMATION (Tables)	9 Months Ended
	Sep. 30, 2018
Segment Reporting [Abstract]
Schedule of revenue earned from countries	For the nine months ended September 30, 2018 and 2017, the Company earned revenue from countries as outlined in the table below: Country Revenue for the Nine Months Ended September 30, 2018 % of Total Revenue for the Nine Months Ended September 30, 2018 Revenue for the Nine Months Ended September 30, 2017 % of Total Revenue for the Nine Months Ended September 30, 2017 United States $ 7,669,989 93.1 % $ 66,545 19.2 % Japan 128,644 1.6 % 119,033 32.5 % Taiwan 137,821 1.7 % 180,854 49.4 % France 233,220 2.8 % — 0.0 % Other 64,983 0.8 % — — For the three months ended September 30, 2018 and 2017, the Company earned revenue from countries as outlined in the table below: Country Revenue for the Three Months Ended September 30, 2018 % of Total Revenue for the Three Months Ended September 30, 2018 Revenue for the Three Months Ended September 30, 2017 % of Total Revenue for the Three Months Ended September 30, 2017 United States $ 4,697,135 96.2 % $ 25,042 17.8 % Japan 40,705 0.9 % 48,185 34.4 % Taiwan 0.0 % 67,087 47.8 % France 89,167 1.8 % — 0.0 % Saudi Arabia 55,239 1.1 % — 0.0 %

SUBSEQUENT EVENTS (Tables)

SUBSEQUENT EVENTS (Tables)	9 Months Ended
	Sep. 30, 2018
Subsequent Events [Abstract]
Schedule of subsequent events	Subsequent to September 30, 2018, the Company issued the following: Principal Amounts Annual Interest Rate Term Conversion Price Senior Secured Debentures $ 12,200,000 10.00% 18 Months N/A

SUMMARY OF SIGNIFICANT ACCOUN_4

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)	Jan. 01, 2018USD ($)	Jun. 12, 2017USD ($)Number	Jun. 12, 2017KRW (₩)Number	Jul. 31, 2017USD ($)shares	Jul. 31, 2017KRW (₩)₩ / sharesshares	Oct. 31, 2016USD ($)shares	Oct. 31, 2016KRW (₩)₩ / sharesshares	Jan. 31, 2009USD ($)shares	Jan. 31, 2009JPY (¥)¥ / sharesshares	Sep. 30, 2018USD ($)$ / sharesshares	Jun. 30, 2018USD ($)	Mar. 31, 2018USD ($)	Sep. 30, 2017USD ($)	Sep. 30, 2018USD ($)Vendor$ / sharesshares	Sep. 30, 2017USD ($)shares	Dec. 31, 2017USD ($)Vendor$ / sharesshares	Sep. 30, 2018¥ / shares	Sep. 30, 2018₩ / shares	Dec. 31, 2017¥ / shares	Dec. 31, 2017₩ / shares
Summary Of Significant Accounting Policy [Line Items]
Net revenue										$ 4,882,246			$ 140,314	$ 8,234,657	$ 366,432
Revenue recognized										700,000
Number of vendors | Vendor														2		1
Advertising costs										16,750			$ 18,201	$ 76,654	$ 35,399
Potentially dilutive securities outstanding | shares														15,286,940	15,617,245
ASU 2016-01 [Member]
Summary Of Significant Accounting Policy [Line Items]
Cumulative effect adjustment on adoption of ASU 2016-01	$ 41,400,000													$ 41,400,000
Cumulative effect on retained earnings, tax	$ 12,300,000													12,300,000
API Supply Agreement [Member] | Telcon, Inc. ("Telcon") [Member]
Summary Of Significant Accounting Policy [Line Items]
Proceeds from supply agreement		$ 31,800,000
API Supply Agreement [Member] | Telcon, Inc. ("Telcon") [Member] | Korea (South), Won
Summary Of Significant Accounting Policy [Line Items]
Proceeds from supply agreement | ₩			₩ 36,000,000,000
2011 Convertible notes payable [Member]
Summary Of Significant Accounting Policy [Line Items]
Convertible notes payable, carrying amount										$ 300,000				$ 300,000		$ 300,000
CellSeed, Inc. [Member]
Summary Of Significant Accounting Policy [Line Items]
Shares held as marketable securities | shares										39,250				39,250
Shares originally purchased (in shares) | shares								147,100	147,100
Investment								$ 1,100,000	¥ 100,028,000
Investment, in per share | ¥ / shares									¥ 680
Investment, closing price | (per share)										$ 8.80				$ 8.80		$ 4.10	¥ 1,001		¥ 462
Stock pledged against note | shares										39,250				39,250		39,250
KPM Tech [Member]
Summary Of Significant Accounting Policy [Line Items]
Shares held as marketable securities | shares						849,744	849,744
Investment						$ 13,000,000	₩ 14,318,186,400
Investment, in per share | ₩ / shares							₩ 16,850
Investment, closing price | (per share)																$ 1.52				₩ 1,625
Hanil Vacuum [Member]
Summary Of Significant Accounting Policy [Line Items]
Shares held as marketable securities | shares						271,950	271,950
Investment						$ 1,000,000	₩ 1,101,397,500
Investment, in per share | ₩ / shares							₩ 4,050
Investment, closing price | (per share)																2.65				2,830
Telcon, Inc. ("Telcon") [Member]
Summary Of Significant Accounting Policy [Line Items]
Shares held as marketable securities | shares				6,643,559	6,643,559
Investment				$ 31,800,000	₩ 36,001,446,221
Investment, in per share | ₩ / shares					₩ 5,419
Investment, closing price | (per share)										$ 9.27				$ 9.27		$ 13.95		₩ 10,300		₩ 14,900
Telcon, Inc. ("Telcon") [Member] | API Supply Agreement [Member]
Summary Of Significant Accounting Policy [Line Items]
Stock pledged against supply agreement | shares										6,643,559				6,643,559		6,643,559
Proceeds from supply agreement		$ 31,800,000												$ 31,800,000		$ 31,800,000
Telcon, Inc. ("Telcon") [Member] | API Supply Agreement [Member] | Korea (South), Won
Summary Of Significant Accounting Policy [Line Items]
Proceeds from supply agreement | ₩			₩ 36,000,000,000
Endari [Member]
Summary Of Significant Accounting Policy [Line Items]
Gross sales										$ 5,500,000	$ 3,800,000	$ 1,300,000
Net revenue										$ 4,700,000	$ 2,300,000	$ 700,000
Pharmaceutical Grade L-glutamine [Member] | API Supply Agreement [Member] | Telcon, Inc. ("Telcon") [Member]
Summary Of Significant Accounting Policy [Line Items]
Percentage of right to supply		25.00%	25.00%
Agreement term		5 years	5 years
Number of renewals | Number		10	10
Pharmaceutical Grade L-glutamine [Member] | Telcon, Inc. ("Telcon") [Member] | API Supply Agreement [Member]
Summary Of Significant Accounting Policy [Line Items]
Percentage of right to supply		25.00%	25.00%
Agreement term		15 years	15 years

SUMMARY OF SIGNIFICANT ACCOUN_5

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details 1) - USD ($)	Sep. 30, 2018	Dec. 31, 2017
Inventories by category
Raw materials and components	$ 184,126
Work-in-process	924,275	$ 124,801
Finished goods	2,238,828	500,498
Total	$ 3,347,229	$ 625,299

SUMMARY OF SIGNIFICANT ACCOUN_6

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details 2) - USD ($)	Sep. 30, 2018	Dec. 31, 2017
Accounting Policies [Abstract]
Prepaid insurance	$ 72,510	$ 132,387
Other prepaid expenses and current assets	246,633	157,984
Total prepaid expenses	$ 319,143	$ 290,371

SUMMARY OF SIGNIFICANT ACCOUN_7

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details 3) - USD ($)	Sep. 30, 2018	Dec. 31, 2017
Summary Of Significant Accounting Policy [Line Items]
Other long-term liabilities	$ 39,531,500	$ 36,852,290
Other Long-Term Liabilities [Member]
Summary Of Significant Accounting Policy [Line Items]
Other long-term liabilities		10,790
Unearned Revenue [Member]
Summary Of Significant Accounting Policy [Line Items]
Other long-term liabilities	10,000,000	5,000,000
Trade Discount [Member]
Summary Of Significant Accounting Policy [Line Items]
Other long-term liabilities	$ 29,531,500	$ 31,841,500

SUMMARY OF SIGNIFICANT ACCOUN_8

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details 4) - USD ($)	9 Months Ended	12 Months Ended
	Sep. 30, 2018	Dec. 31, 2017
Warrant Derivative Liabilities - Stock Purchase Warrants [Member] | Level 3 [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Balance, beginning of period	$ 26,377,000	$ 10,600,000
Repurchased	(6,186,000)
Change in fair value included in the statement of comprehensive income (loss)	(20,191,000)	15,777,000
Balance, end of period		26,377,000
Liability Instrument - Warrants [Member] | GPB Debt Holdings II, LLC [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Balance, beginning of period	1,882,000
Fair value at issuance date		1,882,000
Change in fair value included in the statement of comprehensive income (loss)	(160,000)
Balance, end of period	1,722,000	1,882,000
Liability Instrument - Embedded Conversion Option [Member] | GPB Debt Holdings II, LLC [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Balance, beginning of period	1,289,000
Fair value at issuance date		1,289,000
Change in fair value included in the statement of comprehensive income (loss)	(466,000)
Extinguished upon debt repayment	$ (823,000)
Balance, end of period		$ 1,289,000

SUMMARY OF SIGNIFICANT ACCOUN_9

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details 5)	Sep. 30, 2018USD ($)$ / sharesshares	Dec. 31, 2017USD ($)$ / sharesshares
Summary Of Significant Accounting Policy [Line Items]
Stock price | $ / shares	$ 11.10	$ 11.40
Class Of Warrant Or Right Outstanding1 | shares	240,764	240,764
Warrant derivative liabilities | $	$ 1,722,000	$ 1,882,000
Measurement Input, Risk Free Interest Rate
Summary Of Significant Accounting Policy [Line Items]
Warrants and rights outstanding, measurement input	2.92	2.20
Measurement Input, Price Volatility
Summary Of Significant Accounting Policy [Line Items]
Warrants and rights outstanding, measurement input	70	70
Measurement Input, Expected Term
Summary Of Significant Accounting Policy [Line Items]
Expected life (in years)	4 years 3 months	5 years

SUMMARY OF SIGNIFICANT ACCOU_10

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details 6)	9 Months Ended
	Sep. 30, 2018USD ($)$ / shares$ / Warrantshares
Summary Of Significant Accounting Policy [Line Items]
Original Loan Principal Amount	$ 62,615,104
Beneficial Conversion Discount Amount	$ 21,897,334
Warrants Issued with Notes (in shares) | shares	240,764
Warrant FMV Discount Amount	$ 1,882,000
Minimum [Member]
Summary Of Significant Accounting Policy [Line Items]
Conversion Rate (in dollars per share) | $ / shares	$ 3.05
Maximum [Member]
Summary Of Significant Accounting Policy [Line Items]
Conversion Rate (in dollars per share) | $ / shares	$ 10
2017 Convertible Notes Payable [Member]
Summary Of Significant Accounting Policy [Line Items]
Original Loan Principal Amount	$ 36,113,296
Beneficial Conversion Discount Amount	$ 11,678,725
Warrants Issued with Notes (in shares) | shares	240,764
Exercise Price (in dollars per share) | $ / Warrant	10.80
Warrant FMV Discount Amount	$ 1,882,000
2017 Convertible Notes Payable [Member] | Minimum [Member]
Summary Of Significant Accounting Policy [Line Items]
Term of Loan	Due on demand
Stated Annual Interest	10.00%
Conversion Rate (in dollars per share) | $ / shares	$ 3.50
Effective Interest Rate Including Discounts	10.00%
2017 Convertible Notes Payable [Member] | Maximum [Member]
Summary Of Significant Accounting Policy [Line Items]
Term of Loans	3 years
Stated Annual Interest	13.50%
Conversion Rate (in dollars per share) | $ / shares	$ 10.31
Effective Interest Rate Including Discounts	110.00%
2018 Convertible Notes Payable [Member]
Summary Of Significant Accounting Policy [Line Items]
Original Loan Principal Amount	$ 26,501,808
Beneficial Conversion Discount Amount	$ 10,218,609
2018 Convertible Notes Payable [Member] | Minimum [Member]
Summary Of Significant Accounting Policy [Line Items]
Term of Loan	Due on demand
Stated Annual Interest	6.00%
Conversion Rate (in dollars per share) | $ / shares	$ 3.50
Effective Interest Rate Including Discounts	19.00%
2018 Convertible Notes Payable [Member] | Maximum [Member]
Summary Of Significant Accounting Policy [Line Items]
Term of Loans	2 years
Stated Annual Interest	10.00%
Conversion Rate (in dollars per share) | $ / shares	$ 10
Effective Interest Rate Including Discounts	110.00%

PROPERTY AND EQUIPMENT (Details

PROPERTY AND EQUIPMENT (Details) - USD ($)	Sep. 30, 2018	Dec. 31, 2017
Property and equipment
Property and equipment, gross	$ 441,462	$ 360,759
Less: accumulated depreciation	(288,972)	(255,457)
Property and equipment, net	152,490	105,302
Equipment [Member]
Property and equipment
Property and equipment, gross	292,212	225,615
Leasehold Improvements [Member]
Property and equipment
Property and equipment, gross	70,249	61,054
Furniture and Fixtures [Member]
Property and equipment
Property and equipment, gross	$ 79,001	$ 74,090

PROPERTY AND EQUIPMENT (Detai_2

PROPERTY AND EQUIPMENT (Details Narrative) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Property Plant And Equipment [Abstract]
Depreciation expense	$ 12,843	$ 9,236	$ 33,591	$ 18,593

INVESTMENTS (Details Narrative)

INVESTMENTS (Details Narrative) - USD ($)	Jan. 01, 2018	Sep. 30, 2018	Dec. 31, 2017
Schedule Of Investments [Line Items]
Marketable equity securities classified as trading, value			$ 0
Cost method investments, carrying value			$ 65,520
ASU 2016-01 [Member]
Schedule Of Investments [Line Items]
Cumulative effect adjustment on adoption of ASU 2016-01	$ 41,400,000	$ 41,400,000
Cumulative effect on retained earnings, tax	$ 12,300,000	$ 12,300,000

INVESTMENTS (Details 1)

INVESTMENTS (Details 1) - USD ($)	Sep. 30, 2018	Dec. 31, 2017
Schedule Of Investments [Line Items]
Equity securities	$ 61,931,302	$ 100,062,842
Other investments	572,199
Total equity securities	572,199
Marketable Equity Securties [Member]
Schedule Of Investments [Line Items]
Equity securities	$ 61,931,302	$ 99,997,322

INVESTMENTS (Details 2)

INVESTMENTS (Details 2) - USD ($)	3 Months Ended	9 Months Ended	12 Months Ended
	Sep. 30, 2018	Sep. 30, 2018	Dec. 31, 2017
Investments [Abstract]
Net losses recognized during the period related to equity securities		$ (31,626,779)
Less: Net gain (loss) recognized during the period related to equity securities sold during the period	$ (7,560,760)	(7,560,760)
Unrealized gain (loss) recognized during the period related to equity securities still held at the end of the period	$ 9,583,295	$ (24,066,019)	$ 100,062,842

INVESTMENTS (Details 3)

INVESTMENTS (Details 3) - USD ($)	3 Months Ended	9 Months Ended	12 Months Ended
	Sep. 30, 2018	Sep. 30, 2018	Dec. 31, 2017
Investments [Abstract]
Available-for-sale securities			$ 46,209,017
Total equity securities			46,209,017
Available-for-sale securities			60,812,231
Total equity securities			60,812,231
Available-for-sale securities			(6,958,406)
Total equity securities			(6,958,406)
Available-for-sale securities			100,062,842
Total equity securities	$ 9,583,295	$ (24,066,019)	$ 100,062,842

INVESTMENTS (Details 4)

INVESTMENTS (Details 4) - USD ($)	Sep. 30, 2018	Dec. 31, 2017
Schedule Of Investments [Line Items]
Available-for-Sale Securities	$ 61,931,302	$ 100,062,842
Marketable Equity Securties [Member]
Schedule Of Investments [Line Items]
Available-for-Sale Securities	$ 61,931,302	99,997,322
Long-Term Investment At Cost [Member]
Schedule Of Investments [Line Items]
Available-for-Sale Securities		$ 65,520

ACCOUNTS PAYABLE AND ACCRUED _3

ACCOUNTS PAYABLE AND ACCRUED EXPENSES (Details) - USD ($)	Sep. 30, 2018	Dec. 31, 2017
Accounts payable:
Regulatory fees		$ 715,999
Clinical and regulatory expenses	$ 296,316	116,736
Commercialization consulting fees	8,544	30,000
Manufacturing cost	394,093	217,155
Legal expenses	60,526	87,701
Consulting fees	224,850	147,038
Accounting fees	25,770	67,293
Selling expenses	380,604	35,383
Investor relations and public relations expenses		45,526
Board member compensation	278,740	11,200
Other vendors	976,095	125,605
Total accounts payable	2,645,538	1,599,636
Accrued interest payable, related parties	506,322	318,120
Accrued interest payable	1,976,563	1,449,154
Accrued expenses:
Wages and payroll taxes payable	95,021	1,711,541
Deferred salary	291,667	291,667
Paid vacation payable	251,288	186,978
Other accrued expenses	1,775,627	138,214
Total accrued expenses	2,413,603	2,328,400
Total accounts payable and accrued expenses	$ 7,542,026	$ 5,695,310

NOTES PAYABLE (Details)

NOTES PAYABLE (Details)	9 Months Ended	12 Months Ended
	Sep. 30, 2018USD ($)Number$ / shares	Dec. 31, 2017USD ($)Number
Principal Outstanding	$ 49,992,525	$ 48,723,907
Discount Amount	4,862,817	11,315,721
Carrying Amount	$ 45,129,708	$ 37,408,186
Shares Underlying Principal | Number	6,362,532	6,187,614
Notes payable, current	$ 4,384,241	$ 7,871,143
Notes payable, non-current	$ 6,670,000
Minimum [Member]
Conversion Price | $ / shares	$ 3.05
Maximum [Member]
Conversion Price | $ / shares	$ 10
2013 Notes payable [Member]
Interest rate	10.00%
Term of Notes	Due on demand
Principal Outstanding	$ 879,400	887,600
Carrying Amount	$ 879,400	887,600
2015 Notes payable [Member]
Interest rate	10.00%
Term of Notes	Due on demand
Principal Outstanding	$ 10,000
Carrying Amount	$ 10,000
2016 Notes payable [Member]
Term of Notes	Due on demand
Principal Outstanding	$ 843,335	833,335
Carrying Amount	$ 843,335	833,335
2016 Notes payable [Member] | Minimum [Member]
Interest rate	10.00%
2016 Notes payable [Member] | Maximum [Member]
Interest rate	11.00%
2017 Notes payable [Member]
Interest rate	11.00%
Term of Notes	Due on demand
Principal Outstanding	$ 2,540,506	6,150,208
Carrying Amount	2,540,506	6,150,208
2018 Notes payable [Member]
Principal Outstanding	6,811,000
Discount Amount	30,000
Carrying Amount	$ 6,781,000
2018 Notes payable [Member] | Minimum [Member]
Interest rate	10.00%
Term of Notes	Due on demand
2018 Notes payable [Member] | Maximum [Member]
Interest rate	11.00%
Term of Notes	18 months
Notes Payable [Member]
Principal Outstanding	$ 11,084,241	7,871,143
Discount Amount	30,000
Carrying Amount	11,054,241	7,871,143
Principal Outstanding, Current	4,384,241	7,871,143
Notes payable, current	4,384,241	7,871,143
Principal Outstanding, Non Current	6,700,000
Discount Amount Non Current	30,000
Notes payable, non-current	$ 6,670,000
2015 Notes payable - related party [Member]
Interest rate	11.00%
Term of Notes	Due on demand
Principal Outstanding		310,000
Carrying Amount		310,000
2016 Notes payable - related party [Member]
Interest rate	10.00%
Term of Notes	Due on demand
Principal Outstanding	$ 270,000	810,510
Carrying Amount	$ 270,000	810,510
2017 Notes payable - related party [Member]
Interest rate	10.00%
Term of Notes	Due on demand
Principal Outstanding	$ 915,751	915,751
Carrying Amount	$ 915,751	915,751
2018 Notes payable - related party [Member]
Interest rate	11.00%
Term of Notes	Due on demand
Principal Outstanding	$ 159,222
Carrying Amount	159,222
Notes payable - related party [Member]
Principal Outstanding	1,344,973	2,036,261
Carrying Amount	1,344,973	2,036,261
Principal Outstanding, Current	1,344,973	2,036,261
Notes payable, current	$ 1,344,973	$ 2,036,261

NOTES PAYABLE (Details 1)

NOTES PAYABLE (Details 1)	9 Months Ended	12 Months Ended
	Sep. 30, 2018USD ($)Number$ / shares	Dec. 31, 2017USD ($)Number
Principal Outstanding	$ 49,992,525	$ 48,723,907
Discount Amount	4,862,817	11,315,721
Carrying Amount	$ 45,129,708	$ 37,408,186
Shares Underlying Principal | Number	6,362,532	6,187,614
Convertible notes payable, Current	$ 14,137,645	$ 7,025,002
Convertible notes payable, Non Current	$ 5,258,462	20,075,780
Minimum [Member]
Conversion Price | $ / shares	$ 3.05
Maximum [Member]
Conversion Price | $ / shares	$ 10
2011 Convertible notes payable [Member]
Interest rate	10.00%
Term of Notes	5 years
Conversion Price | $ / shares	$ 3.05
Principal Outstanding	$ 300,000	300,000
Carrying Amount	$ 300,000	$ 300,000
Shares Underlying Principal | Number	98,285	98,285
2014 Convertible notes payable [Member]
Interest rate	10.00%
Principal Outstanding	$ 501,273	$ 486,878
Carrying Amount	$ 501,273	$ 486,878
Shares Underlying Principal | Number	176,777	168,766
2014 Convertible notes payable [Member] | Minimum [Member]
Term of Notes	Due on demand
Conversion Price | $ / shares	$ 3.05
2014 Convertible notes payable [Member] | Maximum [Member]
Term of Notes	2 years
Conversion Price | $ / shares	$ 3.60
2016 Convertible Notes Payable [Member]
Interest rate	10.00%
Principal Outstanding	$ 182,495	$ 1,516,329
Discount Amount	7,952	83,298
Carrying Amount	$ 174,543	$ 1,433,031
Shares Underlying Principal | Number	55,983	441,048
2016 Convertible Notes Payable [Member] | Minimum [Member]
Term of Notes	1 year
Conversion Price | $ / shares	$ 3.60
2016 Convertible Notes Payable [Member] | Maximum [Member]
Term of Notes	2 years
Conversion Price | $ / shares	$ 4.50
2017 Convertible Notes Payable [Member]
Interest rate	10.00%
Principal Outstanding	$ 5,256,547	$ 36,113,296
Discount Amount	947,731	11,232,423
Carrying Amount	$ 4,308,816	$ 24,880,873
Shares Underlying Principal | Number	1,441,824	5,357,488
2017 Convertible Notes Payable [Member] | Minimum [Member]
Term of Notes	Due on demand
Conversion Price | $ / shares	$ 3.50
2017 Convertible Notes Payable [Member] | Maximum [Member]
Term of Notes	2 years
Conversion Price | $ / shares	$ 10
2018 Convertible Notes Payable [Member]
Principal Outstanding	$ 16,522,996
Discount Amount	2,411,522
Carrying Amount	$ 14,111,474
Shares Underlying Principal | Number	2,983,385
2018 Convertible Notes Payable [Member] | Minimum [Member]
Interest rate	6.00%
Term of Notes	Due on demand
Conversion Price | $ / shares	$ 3.50
2018 Convertible Notes Payable [Member] | Maximum [Member]
Interest rate	10.00%
Term of Notes	2 years
Conversion Price | $ / shares	$ 10
Convertible Notes Payable [Member]
Principal Outstanding	$ 22,763,311	$ 38,416,503
Discount Amount	3,367,205	11,315,721
Carrying Amount	$ 19,396,106	$ 27,100,782
Shares Underlying Principal | Number	4,756,254	6,065,587
Principal Outstanding, Current	$ 16,256,710	$ 12,860,912
Principal Outstanding, Non Current	6,506,601	25,555,591
Discount Amount Current	2,119,066	5,835,910
Discount Amount Non Current	1,248,139	5,479,811
Convertible notes payable, Current	14,137,644	7,025,002
Convertible notes payable, Non Current	$ 5,258,462	$ 20,075,780
Shares Underlying Principal Current | Number	2,119,066	3,449,984
Shares Underlying Principal Non Current | Number	2,637,188	2,615,603
2012 Convertible notes payable - related party [Member]
Interest rate	10.00%
Term of Notes	Due on demand
Conversion Price | $ / shares	$ 3.30
Principal Outstanding	$ 200,000	$ 200,000
Carrying Amount	$ 200,000	$ 200,000
Shares Underlying Principal | Number	71,127	68,122
2015 Convertible notes payable - related party [Member]
Interest rate	10.00%
Term of Notes	2 years
Conversion Price | $ / shares	$ 4.50
Principal Outstanding	$ 200,000	$ 200,000
Carrying Amount	$ 200,000	$ 200,000
Shares Underlying Principal | Number	56,109	53,905
2017 Convertible notes payable - related party [Member]
Interest rate	10.00%
Term of Notes	2 years
Conversion Price | $ / shares	$ 10
Principal Outstanding	$ 5,000,000
Discount Amount	407,292
Carrying Amount	$ 4,592,708
Shares Underlying Principal | Number	507,465
2018 Convertible notes payable - related party [Member]
Interest rate	10.00%
Term of Notes	2 years
Conversion Price | $ / shares	$ 10
Principal Outstanding	$ 9,400,000
Discount Amount	1,058,320
Carrying Amount	$ 8,341,680
Shares Underlying Principal | Number	971,577
Convertible notes payable - related party [Member]
Principal Outstanding	$ 14,800,000	$ 400,000
Discount Amount	1,465,612
Carrying Amount	$ 13,334,388	$ 400,000
Shares Underlying Principal | Number	1,606,278	122,027
Principal Outstanding, Current	$ 400,000	$ 400,000
Principal Outstanding, Non Current	14,400,000
Discount Amount Non Current	1,465,612
Convertible notes payable, Current	400,000	$ 400,000
Convertible notes payable, Non Current	$ 12,934,388
Shares Underlying Principal Current | Number	127,236	122,027
Shares Underlying Principal Non Current | Number	1,479,042

NOTES PAYABLE (Details Narrativ

NOTES PAYABLE (Details Narrative) - $ / shares	9 Months Ended
	Sep. 30, 2018	Dec. 31, 2017
Average stated interest rate	10.00%	11.00%
Average effective interest rate	38.00%	24.00%
Description of debt conversion	Certain notes with a $4.50 or a $10.00 stated conversion price in the second year of their two-year term are subject to automatic conversion into shares of Company common stock at a conversion price equal to 80% of the initial public offering price at the time of a qualified public offering.
Percentage of initial public offering price	80.00%
Warrants [Member]
Method of calculation of fair value of warrants	Black Scholes Merton Option Pricing Model
Minimum [Member]
Conversion Price	$ 3.05
Maximum [Member]
Conversion Price	$ 10

NOTES PAYABLE (Details 2)

NOTES PAYABLE (Details 2)	Sep. 30, 2018USD ($)
Long Term Debt By Maturity [Abstract]
2018 (three months)	$ 20,894,505
2,019	6,491,419
2,020	22,606,601
Total	$ 49,992,525

NOTES PAYABLE (Details 3)

NOTES PAYABLE (Details 3)	Sep. 30, 2018$ / shares	Dec. 31, 2017$ / shares
Stock price	$ 11.10	$ 11.40
Term [Member]
Term	4 years 3 months	5 years
Risk-free Interest Rate [Member]
Warrants and rights outstanding, measurement input	2.92	2.20
Expected Volatility [Member]
Warrants and rights outstanding, measurement input	70	70
Warrants [Member] | Convertible Notes Payable [Member]
Stock price		$ 11.40
Warrants [Member] | Convertible Notes Payable [Member] | Exercise Price [Member]
Warrants and rights outstanding, measurement input		10.80
Warrants [Member] | Convertible Notes Payable [Member] | Term [Member]
Term		5 years
Warrants [Member] | Convertible Notes Payable [Member] | Risk-free Interest Rate [Member]
Warrants and rights outstanding, measurement input		2.20
Warrants [Member] | Convertible Notes Payable [Member] | Expected Volatility [Member]
Warrants and rights outstanding, measurement input		70

STOCKHOLDERS' DEFICIT (Details

STOCKHOLDERS' DEFICIT (Details Narrative) - USD ($)	Dec. 29, 2017	Sep. 29, 2016	Sep. 12, 2016	Jun. 10, 2015	Jun. 10, 2014	Sep. 11, 2013	Sep. 30, 2018	Sep. 30, 2017	Dec. 31, 2017	Dec. 31, 2016	Sep. 11, 2014	Jun. 10, 2010
Warrants outstanding							2,096,931
Warrants Issued with Notes (in shares)							240,764
Exercise price - options vested									$ 11.40
Share-based compensation							$ 3,742,575	$ 3,751,371
Period remaining for recognition of unrecognized compensation cost							2 years
Letter of Agreement [Member] | KPM Tech Co [Member]
Common stock price			$ 15.32
Future capital increases			$ 13,000,000
Letter of Agreement [Member] | Hanil Vacuum Co [Member]
Common stock price			$ 3.68
Future capital increases			$ 1,000,000
GPB Debt Holdings II, LLC [Member] | Purchase Warrant [Member]
Percent of product of registrable securities and closing sale price liable upon non registration as liquidation damages	2.00%
GPB Debt Holdings II, LLC [Member] | Purchase Warrant [Member] | Maximum [Member]
Penalty percent of product of registrable securities and closing sale price liable upon non registration as liquidation damages	12.00%
2011 Stock Incentive Option Plan [Member]
Options granted							357,000		50,000
Exercise price - options vested							$ 11.28		$ 11.40
Exercise price - options							$ 4.46		$ 4.12	$ 4.10
Options outstanding							6,835,534		6,775,200	6,955,200
Total unrecognized compensation cost							$ 3,800,000
2011 Stock Incentive Option Plan [Member] | Stock Option [Member]
Share-based compensation							$ 3,700,000	$ 3,800,000
2011 Stock Incentive Option Plan [Member] | 2018 Stock Options Tranche 1 [Member]
Options granted							30,000
Exercise price - options							$ 11.40
Vesting percentage							33.00%
2011 Stock Incentive Option Plan [Member] | 2018 Stock Options Tranche 2 [Member]
Options granted							277,000
Exercise price - options							$ 11.30
Vesting period							3 years
2011 Stock Incentive Option Plan [Member] | 2018 Stock Options Tranche 3 [Member]
Options granted							50,000
Exercise price - options							$ 11.10
Vesting period							3 years
Private Placement [Member]
Units issued in offering						3,020,501
Unit price of offering						$ 2.50
Units issued in offering						$ 7,551,253
Warrants issued to broker of the offering						300,000
Exercise price					$ 3.50	$ 3.50
Warrants outstanding											2,225,036
Fair value of outstanding warrants					$ 1,800,000						$ 7,068,000
Number of warrants exercised					1,095,465
Proceeds from exercise of warrants					$ 3,800,000
Issuance of common stock for exercise of warrants					1,095,465
Adjustment to additional paid-in capital - warrants					$ 1,800,000
Private Placement [Member] | Letter of Agreement [Member]
Future capital investment			13,000,000
Reduction in additional paid in capital		$ 720,000
Private Placement [Member] | Letter of Agreement [Member] | KPM Tech Co [Member]
Purchase of common stock			$ 17,000,000
Common stock price			$ 4.50
Number of shares issued		3,777,778
Private Placement [Member] | Letter of Agreement [Member] | Hanil Vacuum Co [Member]
Purchase of common stock			$ 3,000,000
Future capital investment			$ 1,000,000
Number of shares issued		666,667
Private Placement [Member] | Letter of Agreement [Member] | KPM Tech Co And Hanil Vacuum Co [Member]
Purchase of common stock		$ 20,000,000
Private Placement [Member] | Common Class A [Member]
Number of securities												4,115,966
Private Placement [Member] | Warrant [Member]
Number of securities												3,320,501
Private Placement [Member] | Replacement Warrants [Member]
Exercise price												$ 3.50
Private Placement [Member] | Replacement Warrants [Member]
Exercise price					$ 3.50
Warrants outstanding				1,095,465
Fair value of outstanding warrants				$ 2,545,000
Warrants Issued with Notes (in shares)					1,095,465
Warrant exercise inducement expense				$ 3,500,000

STOCKHOLDERS' DEFICIT (Details)

STOCKHOLDERS' DEFICIT (Details) - shares	9 Months Ended	12 Months Ended
	Sep. 30, 2018	Dec. 31, 2017
Warrants outstanding, ending	2,096,931
Warrant [Member]
Warrants outstanding, beginning	5,265,432	5,024,668
Granted	202,000	240,764
Exercised	(2,384,817)
Cancelled, forfeited and expired	(985,684)
Warrants outstanding, ending	2,096,931	5,265,432

STOCKHOLDERS' DEFICIT (Detail_2

STOCKHOLDERS' DEFICIT (Details 1)	9 Months Ended
	Sep. 30, 2018$ / sharesshares
Outstanding	2,096,931
Exercisable	2,096,931
Warrants Issued in 2014 - Exercise Price $3.50 [Member]
Outstanding	50,000
Outstanding	6 months 29 days
Outstanding | $ / shares	$ 3.50
Exercisable	50,000
Exercisable | $ / shares	$ 3.50
Warrants Issued in 2014 [Member]
Outstanding	50,000
Exercisable	50,000
Warrants Issued in 2015 - Exercise Price $4.90 [Member]
Outstanding	110,417
Outstanding	1 year 5 months 4 days
Outstanding | $ / shares	$ 4.90
Exercisable	110,417
Exercisable | $ / shares	$ 4.90
Warrants Issued in 2015 [Member]
Outstanding	110,417
Exercisable	110,417
Warrants Issued in 2016 - Exercise Price $4.50 [Member]
Outstanding	118,750
Outstanding	2 years 9 months
Outstanding | $ / shares	$ 4.50
Exercisable	118,750
Exercisable | $ / shares	$ 4.50
Warrants Issued in 2016 - Exercise Price $4.70 [Member]
Outstanding	75,000
Outstanding	2 years 7 months 2 days
Outstanding | $ / shares	$ 4.70
Exercisable	75,000
Exercisable | $ / shares	$ 4.70
Warrants Issued in 2016 - Exercise Price $5.00 [Member]
Outstanding	1,300,000
Outstanding	2 years 7 months 9 days
Outstanding | $ / shares	$ 5
Exercisable	1,300,000
Exercisable | $ / shares	$ 5
Warrants Issued in 2016 [Member]
Outstanding	1,493,750
Exercisable	1,493,750
Warrants Issued in 2017 - Exercise Price $ 10.80 [Member]
Outstanding	240,764
Outstanding	4 years 9 months
Outstanding | $ / shares	$ 10.80
Exercisable	240,764
Exercisable | $ / shares	$ 10.80
Warrants Issued in 2017 [Member]
Outstanding	240,764
Exercisable	240,764
Warrants Issued in 2018 - Exercise Price $4.86 [Member]
Outstanding	202,000
Outstanding	4 years 10 months 9 days
Outstanding | $ / shares	$ 11.30
Exercisable	202,000
Exercisable | $ / shares	$ 11.30

STOCKHOLDERS' DEFICIT (Detail_3

STOCKHOLDERS' DEFICIT (Details 3) - $ / shares	9 Months Ended	12 Months Ended
	Sep. 30, 2018	Dec. 31, 2017
Exercise price - options vested		$ 11.40
2011 Stock Incentive Option Plan [Member]
Options outstanding, beginning	6,775,200	6,955,200
Granted or deemed issued	357,000	50,000
Exercised	(170,000)	(11,895)
Cancelled, forfeited and expired	(126,666)	(218,105)
Options outstanding, end	6,835,534	6,775,200
Options exercisable	5,985,823	5,604,439
Options available for future grant	2,164,466	2,224,800
Options outstanding, beginning	$ 4.12	$ 4.10
Exercise price - options vested	11.28	11.40
Exercised	4.59	4.19
Cancelled, forfeited and expired	5.43	4.98
Options outstanding, end	4.46	4.12
Options exercisable	$ 4.02	$ 3.95

COMMITMENTS AND CONTINGENCIES_2

COMMITMENTS AND CONTINGENCIES (Details Narrative)

Oct. 31, 2018$ / shares

Sep. 29, 2017$ / sharesshares

Jul. 12, 2017USD ($)Numberkg$ / kg

Jun. 12, 2017USD ($)$ / sharesshares

Jun. 12, 2017KRW (₩)₩ / shares

Jul. 31, 2017USD ($)

Jul. 31, 2017KRW (₩)₩ / shares

Sep. 30, 2018USD ($)$ / shares

Sep. 30, 2017USD ($)

Sep. 30, 2018USD ($)$ / shares

Sep. 30, 2017USD ($)

Dec. 31, 2017USD ($)$ / shares

Sep. 30, 2018₩ / shares

Dec. 31, 2017₩ / shares

Rent expense

$ 190,903

$ 134,585

$ 493,312

$ 427,687

Telcon, Inc. ("Telcon") [Member]

Investment

$ 31,800,000

₩ 36,001,446,221

Investment, in per share | ₩ / shares

₩ 5,419

Investment, closing price | (per share)

$ 9.27

$ 9.27

$ 13.95

₩ 10,300

₩ 14,900

Telcon, Inc. ("Telcon") [Member] | Subsequent Event [Member]

Share repurchases, initial price per share | $ / shares

$ 7.60

Telcon, Inc. ("Telcon") [Member] | Management Control Acquistion Agreement [Member]

Investment

$ 31,800,000

Investment, closing price | $ / shares

$ 4.79

Ownership interest

10.30%

Telcon, Inc. ("Telcon") [Member] | Management Control Acquistion Agreement [Member] | Korea (South), Won

Investment | ₩

₩ 36,000,000,000

Shares originally purchased (in shares) | shares

6,643,559

Investment, in per share | ₩ / shares

₩ 5,419

Telcon, Inc. ("Telcon") [Member] | API Supply Agreement [Member]

Proceeds from supply agreement

$ 31,800,000

$ 31,800,000

$ 31,800,000

Telcon, Inc. ("Telcon") [Member] | API Supply Agreement [Member] | Pharmaceutical Grade L-glutamine [Member]

Percentage of right to supply

25.00%

25.00%

Agreement term

15 years

15 years

Telcon, Inc. ("Telcon") [Member] | API Supply Agreement [Member] | Korea (South), Won

Proceeds from supply agreement | ₩

₩ 36,000,000,000

Telcon, Inc. ("Telcon") [Member] | Revised API Agreement [Member]

Agreement term

5 years

Number of renewals | Number

10

Weight of drug per supply agreement | kg

940,000

Unit price of grade L-glutamine | $ / kg

50

Purchase amount

$ 47,000,000

Telcon, Inc. ("Telcon") [Member] | Revised API Agreement [Member] | Maximum [Member]

Agreement term

15 years

Yearly purchase commitments

$ 2,500,000

Telcon, Inc. ("Telcon") [Member] | Revised API Agreement [Member] | Minimum [Member]

Yearly purchase commitments

$ 5,000,000

KPM Tech Co And Hanil Vacuum Co [Member] | Telcon, Inc. ("Telcon") [Member]

Number of shares issued | shares

4,444,445

Common stock price | $ / shares

$ 6.60

COMMITMENTS AND CONTINGENCIES_3

COMMITMENTS AND CONTINGENCIES (Details)	Sep. 30, 2018USD ($)
Future minimum lease payments
2018 (three months)	$ 177,959
2,019	722,092
2,020	637,306
2,021	626,545
2,022	646,047
Thereafter	777,344
Total	$ 3,587,293

RELATED PARTY TRANSACTIONS (Det

RELATED PARTY TRANSACTIONS (Details)		9 Months Ended		12 Months Ended
		Sep. 30, 2018USD ($)Number$ / shares		Dec. 31, 2017USD ($)Number$ / shares
Short-term Debt [Line Items]
Principal Amount Outstanding		$ 45,129,708		$ 37,408,186
Shares Underlying Principal | Number		6,362,532		6,187,614
Masaharu & Emiko Osato [Member]
Short-term Debt [Line Items]
Interest Rate		11.00%	[1]	11.00%	[2]
Date of Loan		Dec. 29, 2015	[1]	Dec. 29, 2015	[2]
Term of Loan	[1]	Due on Demand
Principal Amount Outstanding	[2]			$ 300,000
Highest Principal Outstanding		$ 300,000	[1]	$ 300,000	[2]
Amount of Principal Repaid	[1]	300,000
Amount of Interest Paid	[1]	$ 76,036
Masaharu & Emiko Osato [Member]
Short-term Debt [Line Items]
Interest Rate		11.00%	[1]	11.00%	[2]
Date of Loan		Feb. 25, 2016	[1]	Feb. 25, 2016	[2]
Term of Loan	[1]	Due on Demand
Principal Amount Outstanding	[2]			$ 400,000
Highest Principal Outstanding		$ 400,000	[1]	$ 400,000	[2]
Amount of Principal Repaid	[1]	400,000
Amount of Interest Paid	[1]	$ 94,389
Lan T. Tran [Member]
Short-term Debt [Line Items]
Interest Rate		10.00%	[3]	11.00%	[4]
Date of Loan		Apr. 29, 2016	[3]	Feb. 10, 2016	[4]
Term of Loan	[3]	Due on Demand
Principal Amount Outstanding		$ 20,000	[3]	$ 130,510	[4]
Highest Principal Outstanding		$ 20,000	[3]	$ 130,510	[4]
Hope Hospice [Member]
Short-term Debt [Line Items]
Interest Rate	[5]	10.00%		10.00%
Date of Loan	[5]	Jun. 3, 2016		Apr. 4, 2016
Term of Loan	[5]	Due on Demand
Principal Amount Outstanding	[5]	$ 250,000
Highest Principal Outstanding	[5]	$ 250,000		$ 50,000
Amount of Principal Repaid	[5]			50,000
Amount of Interest Paid	[5]			$ 8,110
Lan T. Tran [Member]
Short-term Debt [Line Items]
Interest Rate		10.00%	[3]	10.00%	[4]
Date of Loan		Feb. 9, 2017	[3]	Apr. 29, 2016	[4]
Term of Loan	[3]	Due on Demand
Principal Amount Outstanding		$ 12,000	[3]	$ 20,000	[4]
Highest Principal Outstanding		$ 12,000	[3]	$ 20,000	[4]
Yutaka Niihara [Member]
Short-term Debt [Line Items]
Interest Rate		10.00%	[1],[3]	10.00%	[2],[4]
Date of Loan		Sep. 14, 2017	[1],[3]	Sep. 14, 2017	[2],[4]
Term of Loan	[1],[3]	Due on Demand
Principal Amount Outstanding		$ 903,751	[1],[3]	$ 903,751	[2],[4]
Highest Principal Outstanding		$ 903,751	[1],[3]	903,751	[2],[4]
Lan T. Tran [Member]
Short-term Debt [Line Items]
Interest Rate	[3]	10.00%
Date of Loan	[3]	Feb. 10, 2018
Term of Loan	[3]	Due on Demand
Principal Amount Outstanding	[3]	$ 159,222
Highest Principal Outstanding	[3]	$ 159,222
Promissory Note Payable To Related Parties [Member]
Short-term Debt [Line Items]
Term of Loan		Subtotal
Principal Amount Outstanding		$ 1,344,973		2,036,261
Highest Principal Outstanding		2,044,973		3,562,366
Amount of Principal Repaid		700,000		794,339
Amount of Interest Paid		$ 170,425		$ 129,470
Wei Peu Zen [Member]
Short-term Debt [Line Items]
Interest Rate	[1]	10.00%
Date of Loan	[1]	Nov. 6, 2017
Term of Loans	[1]	2 years
Principal Amount Outstanding	[1]	$ 5,000,000
Highest Principal Outstanding	[1]	5,000,000
Amount of Interest Paid	[1]	$ 250,000
Conversion Rate (in dollars per share) | $ / shares	[1]	$ 10
Shares Underlying Principal | Number	[1]	507,465
Profit Preview Int'l Group, Ltd. [Member]
Short-term Debt [Line Items]
Interest Rate	[6]	10.00%
Date of Loan	[6]	Feb. 1, 2018
Term of Loans	[6]	2 years
Principal Amount Outstanding	[6]	$ 4,037,000
Highest Principal Outstanding	[6]	4,037,000
Amount of Interest Paid	[6]	$ 201,850
Conversion Rate (in dollars per share) | $ / shares	[6]	$ 10
Shares Underlying Principal | Number	[6]	420,290
Yasushi Nagasaki [Member]
Short-term Debt [Line Items]
Interest Rate		10.00%	[3]	10.00%	[4]
Date of Loan		Jun. 29, 2012	[3]	Jun. 29, 2012	[4]
Term of Loan	[3]	Due on Demand
Principal Amount Outstanding		$ 200,000	[3]	$ 200,000	[4]
Highest Principal Outstanding		388,800	[3]	388,800	[4]
Amount of Principal Repaid		$ 188,800	[3]	188,800	[4]
Amount of Interest Paid	[4]			$ 57,886
Conversion Rate (in dollars per share) | $ / shares		$ 3.30	[3]	$ 3.30	[4]
Shares Underlying Principal | Number		71,127	[3]	68,122	[4]
Profit Preview Int'l Group, Ltd. [Member]
Short-term Debt [Line Items]
Interest Rate	[6]	10.00%
Date of Loan	[6]	Mar. 21, 2018
Term of Loans	[6]	2 years
Principal Amount Outstanding	[6]	$ 5,363,000
Highest Principal Outstanding	[6]	5,363,000
Amount of Interest Paid	[6]	$ 268,150
Conversion Rate (in dollars per share) | $ / shares	[6]	$ 10
Shares Underlying Principal | Number	[6]	551,287
Yutaka & Soomi Niihara [Member]
Short-term Debt [Line Items]
Interest Rate		10.00%	[1],[3]	10.00%	[2],[4]
Date of Loan		Nov. 16, 2015	[1],[3]	Nov. 16, 2015	[2],[4]
Term of Loans		2 years	[1],[3]	2 years	[2],[4]
Principal Amount Outstanding		$ 200,000	[1],[3]	$ 200,000	[2],[4]
Highest Principal Outstanding		$ 200,000	[1],[3]	$ 200,000	[2],[4]
Conversion Rate (in dollars per share) | $ / shares		$ 4.50	[1],[3]	$ 4.50	[2],[4]
Shares Underlying Principal | Number		56,109	[1],[3]	53,905	[2],[4]
Convertible notes payable - related party non-current [Member]
Short-term Debt [Line Items]
Principal Amount Outstanding		$ 14,400,000
Highest Principal Outstanding		14,400,000
Amount of Interest Paid		$ 720,000
Shares Underlying Principal | Number		1,479,042
Convertible notes payable - related party current [Member]
Short-term Debt [Line Items]
Principal Amount Outstanding		$ 400,000		$ 400,000
Highest Principal Outstanding		588,800		608,800
Amount of Principal Repaid		$ 188,800		208,800
Amount of Interest Paid				$ 62,291
Shares Underlying Principal | Number		127,236		122,027
Promissory note payable and convertible notes payable - related party [Member]
Short-term Debt [Line Items]
Principal Amount Outstanding		$ 16,144,973		$ 2,436,261
Highest Principal Outstanding		17,033,773		4,171,166
Amount of Principal Repaid		888,800		1,003,139
Amount of Interest Paid		$ 890,425		$ 191,761
Shares Underlying Principal | Number		1,606,278		122,027
Hope Hospice [Member]
Short-term Debt [Line Items]
Interest Rate	[5]			8.00%
Date of Loan	[5]			Jan. 17, 2012
Highest Principal Outstanding	[5]			$ 200,000
Amount of Principal Repaid	[5]			200,000
Amount of Interest Paid	[5]			$ 7,331
Hope Hospice [Member]
Short-term Debt [Line Items]
Interest Rate	[5]			8.00%
Date of Loan	[5]			Jun. 14, 2012
Highest Principal Outstanding	[5]			$ 200,000
Amount of Principal Repaid	[5]			200,000
Amount of Interest Paid	[5]			$ 14,762
Hope Hospice [Member]
Short-term Debt [Line Items]
Interest Rate	[5]			8.00%
Date of Loan	[5]			Jun. 21, 2012
Highest Principal Outstanding	[5]			$ 100,000
Amount of Principal Repaid	[5]			100,000
Amount of Interest Paid	[5]			$ 7,249
Hope Hospice [Member]
Short-term Debt [Line Items]
Interest Rate	[5]			8.00%
Date of Loan	[5]			Feb. 11, 2013
Highest Principal Outstanding	[5]			$ 50,000
Amount of Principal Repaid	[5]			50,000
Amount of Interest Paid	[5]			$ 1,559
Hope Hospice [Member]
Short-term Debt [Line Items]
Interest Rate	[5]			10.00%
Date of Loan	[5]			Jan. 7, 2015
Highest Principal Outstanding	[5]			$ 100,000
Amount of Principal Repaid	[5]			100,000
Amount of Interest Paid	[5]			$ 28,630
IRA Service Trust Co. FBO Peter B. Ludlum [Member]
Short-term Debt [Line Items]
Interest Rate	[4]			10.00%
Date of Loan	[4]			Feb. 20, 2015
Principal Amount Outstanding	[4]			$ 10,000
Highest Principal Outstanding	[4]			$ 10,000
Yutaka Niihara [Member]
Short-term Debt [Line Items]
Interest Rate	[2],[4]			10.00%
Date of Loan	[2],[4]			May 21, 2015
Highest Principal Outstanding	[2],[4]			$ 826,105
Amount of Principal Repaid	[2],[4]			94,339
Amount of Interest Paid	[2],[4]			$ 61,829
IRA Service Trust Co. FBO Peter B. Ludlum Member]
Short-term Debt [Line Items]
Interest Rate	[4]			10.00%
Date of Loan	[4]			May 5, 2016
Principal Amount Outstanding	[4]			$ 10,000
Highest Principal Outstanding	[4]			$ 10,000
Hope Hospice [Member]
Short-term Debt [Line Items]
Interest Rate	[5]			10.00%
Date of Loan	[5]			Jun. 3, 2016
Principal Amount Outstanding	[5]			$ 250,000
Highest Principal Outstanding	[5]			$ 250,000
Lan T. Tran [Member]
Short-term Debt [Line Items]
Interest Rate	[4]			10.00%
Date of Loan	[4]			Feb. 9, 2017
Principal Amount Outstanding	[4]			$ 12,000
Highest Principal Outstanding	[4]			$ 12,000
Charles & Kimxa Stark [Member]
Short-term Debt [Line Items]
Interest Rate	[4]			10.00%
Date of Loan	[4]			Oct. 1, 2015
Term of Loans	[4]			2 years
Highest Principal Outstanding	[4]			$ 20,000
Amount of Principal Repaid	[4]			20,000
Amount of Interest Paid	[4]			$ 4,405
Conversion Rate (in dollars per share) | $ / shares	[4]			$ 4.50
[1]	Director.
[2]	Director
[3]	Officer.
[4]	Officer
[5]	Dr. Niihara, a Director and Chief Executive Officer of the Company, is also the Chief Executive Officer of Hope Hospice.
[6]	Mr. Zen, a Director, is the sole owner of Profit Preview Int'l Group, Ltd.

GEOGRAPHIC INFORMATION (Details

GEOGRAPHIC INFORMATION (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
United States [Member]
Entity Wide Revenue Major Customer [Line Items]
Revenue	$ 4,697,135	$ 25,042	$ 7,669,989	$ 66,545
Percentage of revenue (in percent)	96.20%	17.80%	93.10%	19.20%
Japan [Member]
Entity Wide Revenue Major Customer [Line Items]
Revenue	$ 40,705	$ 48,185	$ 128,644	$ 119,033
Percentage of revenue (in percent)	0.90%	34.40%	1.60%	32.50%
Taiwan [Member]
Entity Wide Revenue Major Customer [Line Items]
Revenue		$ 67,087	$ 137,821	$ 180,854
Percentage of revenue (in percent)	0.00%	47.80%	1.70%	49.40%
France [Member]
Entity Wide Revenue Major Customer [Line Items]
Revenue	$ 89,167		$ 233,220
Percentage of revenue (in percent)	1.80%	0.00%	2.80%	0.00%
Other [Member]
Entity Wide Revenue Major Customer [Line Items]
Revenue			$ 64,983
Percentage of revenue (in percent)			0.80%
Saudi Arabia [Member]
Entity Wide Revenue Major Customer [Line Items]
Revenue	$ 55,239
Percentage of revenue (in percent)	1.10%	0.00%

SUBSEQUENT EVENTS (Details)

SUBSEQUENT EVENTS (Details) - USD ($)	Oct. 01, 2018	Sep. 30, 2018
Principal Amounts		$ 62,615,104
Senior Secured Debentures [Member] | Subsequent Event [Member]
Principal Amounts	$ 12,200,000
Stated Annual Interest	10.00%
Term of Notes	18 months

SUBSEQUENT EVENTS (Details Narr

SUBSEQUENT EVENTS (Details Narrative) $ / shares in Units, ¥ in Billions	1 Months Ended	9 Months Ended
	Oct. 31, 2018USD ($)$ / sharesshares	Sep. 30, 2018USD ($)	Oct. 09, 2018USD ($)	Oct. 09, 2018JPY (¥)
Principal amount of debentures and warrants		$ 62,615,104
Warrants exercisable term		5 years
Date from which warrants are exercisable		Apr. 22, 2019
Subsequent Event [Member]
Exercise price | $ / shares	$ 11.30
Subsequent Event [Member] | T.R. Winston & Company, LLC [Member]
Cash fee paid as percentage of gross proceeds from purchasers	5.00%
Subsequent Event [Member] | EJ Holding, Inc. [Member]
Unsecured long-term debt			$ 13,200,000	¥ 1.5
Percentage of ownership			40.00%	40.00%
Subsequent Event [Member] | 10% Redeemable Debenture [Member]
Stated Annual Interest	10.00%
Debt instrument maturity date	Apr. 21, 2020
Amount of Principal Repaid	$ 1,000,000
Securities Purchase Agreement [Member]
Purchase price consideration received as advance against debentures and warrants		$ 6,700,000
Securities Purchase Agreement [Member] | Subsequent Event [Member]
Principal amount of debentures and warrants	$ 12,200,000
Maximum [Member] | Subsequent Event [Member] | T.R. Winston & Company, LLC [Member]
Number of shares issued | shares	120,000
Maximum [Member] | Securities Purchase Agreement [Member] | Subsequent Event [Member]
Number of shares issued | shares	1,220,000
Minimum [Member] | Subsequent Event [Member] | 10% Redeemable Debenture [Member]
Debt instrument redemption amount	$ 20,000,000